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Colorectal cancer is the third most common form of cancer in developed countries and, despite the improvements achieved
in its treatment options, remains as one of the main causes of cancer-related death. In this review, we first focus on colorectal
carcinogenesis and on the genetic and epigenetic alterations involved. In addition, noncoding RNAs have been shown to be
important regulators of gene expression. We present a general overview of what is known about these molecules and their role
and dysregulation in cancer, with a special focus on the biogenesis, characteristics, and function of microRNAs. These molecules
are important regulators of carcinogenesis, progression, invasion, angiogenesis, and metastases in cancer, including colorectal
cancer. For this reason, miRNAs can be used as potential biomarkers for diagnosis, prognosis, and efficacy of chemotherapeutic
treatments, or even as therapeutic agents, or as targets by themselves. Thus, this review highlights the importance of miRNAs in
the development, progression, diagnosis, and therapy of colorectal cancer and summarizes current therapeutic approaches for the
treatment of colorectal cancer.
1. Introduction
Colorectal cancer (CRC) is a major global cause of morbidity
and mortality in developed countries. CRC is a heteroge-
neous disease regarding tumor localization and genetic and
racial differences, and multiple interactions with environ-
mental factors, diet, and style of life influence its develop-
ment. CRC risk factors include hereditary components (i.e.,
hereditary nonpolyposis colorectal cancer), predisposal to
polyp formation, large bowel inflammatory diseases, obesity,
high fat diet, alcoholism, smoking, and stress [1–5]. The use
of biomarkers to predict the risk for CRC or the existence
of early stages of the tumor could contribute to decreasing
the development of the disease and allowing early inter-
vention. In this review, we give an overview of colorectal
carcinogenesis mechanisms and therapies that are currently
being used. Among the multiple factors involved in CRC
development andprogression, in the last years, the noncoding
RNA molecules have been identified as important factors
regulating many biological pathways. For this reason, we also
focus on the regulatory effects of noncoding RNAs and their
role in CRC development. Among these RNA molecules,
microRNA (miRNAs) expression dysregulation has been
reported as an important factor in the development of CRC.
Moreover, they can also be considered as good biomarkers
for the early detection of CRC in plasma or stool, as well as
predictors of therapy efficacy and as promising tools or targets
for new therapeutic treatments. In addition, other noncoding
RNAs (long noncoding RNAs and circular RNAs) may play
important roles either in CRC-related gene regulation or in
acting as miRNA regulators.
In this review, we first briefly analyze the colonic crypt
organization and the mechanisms of colorectal carcino-
genesis, followed by an initial description of the different
types of noncoding RNAs as new molecules involved in the
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regulation of gene expression.We then analyze the main type
of regulatory RNAs, miRNAs. First, we introduce their gen-
eral characteristics and their biogenesis pathway that leads
to biologically active miRNA-induced silencing complexes
(miRISC). Later on, we present the current knowledge on the
involvement of noncoding RNAs in CRC, beginning with the
dysregulation of the expression of specific miRNAs, the main
signaling pathways involved, and the importance of miRNA
polymorphisms in CRC risk. The role of long noncoding
RNAs and circular RNAs in CRC is also discussed, with
emphasis in the regulation of miRNA function. Finally, we
present colorectal cancer treatments and biomarkers, dis-
cussing first the classical therapies and potential biomarkers
to predict the response to these treatments, followed by an
analysis of the use of miRNAs as diagnostic and prognostic
markers, their involvement in chemo- and radioresistance,
and ending by discussing their potential use as therapeutic
targets and tools in CRC.
2. Colonic Crypt Organization
The adult colonic epithelium, a single sheet of columnar
epithelial cells supported by the lamina propria, has a
well-defined architecture organized into crypts, which are
dynamic structures that are constantly self-renewing (it is
replaced every five days) [16]. The homeostatic self-renewal
of the intestine depends on a complex network of interplay
involving many cellular processes, including proliferation,
differentiation, migration, and apoptosis. All these phenom-
ena are finely coordinated by different signaling pathways
(Wnt, Notch, Ephrin, or antagonists of BMP), playing a
critical role in the Wnt signaling cascade. Wnt signaling
ligands are thought to be produced by mesenchymal cells of
the myofibroblast lineage closely attached to the basal lamina
that surrounds the crypt.
Three differentiated epithelial lineages mediate colonic
function: the colonocytes, or absorptive enterocytes, the
mucus-secreting goblet cells, and the less abundant enteroen-
docrine cells. Each crypt unit is maintained by multipotent
stem cells (SCs), located at the bottom of the crypt. During
asymmetric division, SCs undergo self-renewal and generate
a population of transit-amplifying cells, or progenitors, that,
upon migration upwards the crypt, proliferate and differen-
tiate into one of the epithelial cell types of the intestinal wall.
These cells, enterocytes, goblet cells, and enteroendocrine
cells, continue migrating upwards along the villus until they
reach the villus tipwhere they undergo apoptosis and are shed
into the lumen of the intestine [17].
Transit-amplifying cells and stem cells occupy the lower
two-thirds of colonic crypts [16]. The terminally differenti-
ated cells, which are found in the top third of the crypt, are
continually extruded into the lumen. Adult SCs are defined
by self-renewal, potential for multilineage differentiation,
and tissue regeneration [18]. The “stem cell zone” model
states that small undifferentiated cycling cells (the crypt base
columnar cells) are the true intestinal SCs [17].
3. Colorectal Carcinogenesis
Colorectal cancer, attending to incidence andmortality statis-
tics, is the third most common form of cancer in men and
the second among women. It is one of the main causes of
cancer-related death in themore developed countries, leading
to an incidence of 1.4 million cases and 693,900 CRC-related
deaths occurred in 2012 [19] (http://globocan.iarc.fr). The
incidence and mortality from CRC are markedly lower in
the less developed countries. Epidemiological studies have
shown incidence variations between areas that may be par-
tially explained by varied cultures and lifestyles in different
countries and regions. Factors as the lack of dietary fibers,
smoking, overweight, obesity, physical inactivity, red and
processed meat consumption, and excessive alcohol intake
are potential risks for CRC. Around a quarter of CRC patients
are incurable at diagnosis and half of those who undergo
potentially curative surgerywill ultimately developmetastatic
disease. Despite the emergence of new targeted agents,
early CRC screening, and the use of improved treatments
and various therapeutic combinations, none of the available
treatments is curative in patients with advanced cancer.Thus,
although the application of some medical procedures, such
as the use of colonoscopies or the fecal occult blood test,
contribute greatly to the early diagnosis and CRC treatment,
the deaths from CRC have decreased in several western
countries, but its mortality increased in others, such as some
East Asian or Latin American countries.
CRC is a multifactorial disease, a complex multistep
process involving genetic background, numerous genetic
alterations, and environmental influences [5]. Tumors are
formed by a heterogenic pool of cells with distinct differenti-
ation patterns. Several studies have been directed towards the
identification of markers associated with the initiation and
progression of this type of tumors, which normally involve
multisequential steps along the adenoma-to-carcinoma tran-
sition.The accumulation of mutations in key genes, involving
the inactivation of tumor suppressor genes and oncogene
activation, follows the progression of the disease. Histopatho-
logical and molecular analyses are conducted by Fearon
and Vogelstein to formulate, in the 1990s, the “adenoma-
carcinoma model” or sequence of tumor progression [20].
Thus, the neoplastic process, initiated by APC (Adenomatous
Polyposis Coli) or CTNNB1 (𝛽-catenin) mutations, results
from the sequential mutation of other genes, such as KRAS
and TP53, in the context of a growing genomic instability.
The mechanisms of colorectal carcinogenesis have been
extensively described [1, 3–5, 21]. The two major types of
genomic instability found in colorectal cancers are chromo-
somal instability (CIN) and microsatellite instability (MSI).
CIN is often associated with mutational inactivation of APC
gene. The inactivation of APC is found in about 85% of
sporadic CRC and is mutated in the germline of patients with
FAP (Familial Adenomatous Polyposis). This pathway often
includes activation of oncogenes such as COX2 and KRAS
and inactivation of additional tumor suppressor genes such
asDCC/DPC4 (Deleted in Colon Cancer/Deleted in Pancreatic
Cancer, locus 4) and TP53.
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MSI is due to defective/inactivation of DNA mismatch
repair (MMR) genes. Mutations in these genes cause genetic
defects in other genes that are involved in growth control
and behave like tumor suppressor genes. Lynch syndrome
and hereditary nonpolyposis colorectal cancer (HNPCC)
syndrome are due to inherited mutations in one of the
mismatch repair genes (includingMLH1,MSH2, and PMS2).
MMR mutations are found in approximately the remaining
15% of sporadic CRC [1, 3]. In the CpG island methylator
phenotype, a number of genes become transcriptionally
silenced because of hypermethylation of their promoters, and
this represents a key epigenetic mechanism of inactivation of
tumor suppressor genes, including certain DNA repair genes
[1].
The progression of carcinomas to invasive and metastatic
diseasemay involve localized occurrences of a process known
as the epithelial-mesenchymal transition (EMT). EMT results
in epithelial cells becoming spindle shaped, with loss of
cellular polarity similar to mesenchymal cells. These phe-
notypic changes correlate with increased cellular motility
and invasion ability, more characteristic of mesenchymal
cells. EMT in metastatic colorectal carcinoma has been
studied to identifymolecular events that contribute to disease
progression [22]. Although loss of E-cadherin function is an
initial event in EMT, the expression of specific integrins such
as 𝛼5𝛽6 as a consequence of EMT enables invasive cells to
interact with interstitial matrices and to sustain activation of
TGF-𝛽 (Transforming Growth Factor-𝛽). EMT also induces
autocrine signaling involving VEGF and Flt-1 (its receptor)
enabling invasive cells to become self-sufficient for survival.
Recent research has demonstrated a convincing link between
EMT and cancer stem cells (CSC) as well as their association
with CRC progression and therapeutic resistance [23].
It is well known that tumors are composed by a hetero-
geneous population of cells differing in morphology, marker
expression, proliferation ability, and tumorigenic potential.
But, what is the origin of the tumor cells? Traditional models
of carcinogenesis assumed that this heterogeneity could be
explained by stochastic genetic events and microenviron-
mental influence leading to clonal selection. However, the
stochastic theory for the cellular origin of cancer, based upon
the assumption that all cancer cells are equally malignant
and able to give rise to tumors, has been changed in favor of
the hierarchical theory. The latter assumes that tumor cells
are hierarchically organized and only a rare subpopulation of
undifferentiated cells at the apex of this hierarchy have the
unique biological properties necessary for tumor initiation,
maintenance, and spreading [24]. Evidence is increasingly
supporting the idea that human cancers can be consid-
ered as a stem cell disease. According to the CSC model,
malignancies originate from a small fraction of cancer cells
that show self-renewal and pluripotency and are capable of
initiating and sustaining tumor growth [25]. In this model,
the stem cell-like cells (CSC or tumor-initiating cells) are
capable of propagating a tumor in the same way as normal
stem cells control proliferation and differentiation in normal
tissue [18]. In fact, it is now accepted that CSC can originate
from mutations in normal somatic stem cells that deregulate
their physiological programs. Alternatively, mutations may
target more committed progenitor cells or even mature cells,
which become reprogrammed to acquire stem-like functions.
In any case, mutated genes should promote expansion of
stem/progenitor cells, thus increasing their predisposition to
cancer development by expanding self-renewal and pluripo-
tency over their normal tendency towards relative quiescence
and proper differentiation [26].
In summary, recent evidence points out that cancer can
be considered a disease in which mutations either convert
normal stem cells into aberrant counterparts or induce more
differentiated cells to revert towards a stem cell-like behavior.
This has major implications for the development of new
targeted therapeutic strategies aimed at eradicating the tumor
stem cell population. In fact, CSCs exhibit higher resistance
to cytotoxic drugs and radiation as compared to bulk tumor
cells. Classical therapeutic approaches may preferentially kill
more differentiated cells while sparing CSCs. Survival of even
few CSCs would later result in subsequent tumor regrowth
and disease relapse [27].
The identification CSC populations in human colon
tumors was first published in 2007 by two independent
groups [28, 29]. This subset of cells, identified as CD133+,
was able to initiate tumor growth inmurine xenograftmodels
(∼1 in 262 CD133+ colon cancer cells represented a CSC)
[28]. The expression of CD133 has also been demonstrated
in some tumor cell lines, including Caco-2 cells from human
colon adenocarcinoma [30], and in colorectal tumors and
cells derived from them [28, 29].Moreover, CD44 andCD166
expression can also be used to enrich for a CSC subset in
colon cancers [31]. The use of several cell-surface markers,
such as CD44, CD24, CD133, CD166, EpCAM (epithelial
cell adhesion molecule), and ABCB5 (ATP-binding cassette
subfamily Bmember 5), has successfully allowed the isolation
of CSCs from solid tumors, including human colon, breast,
brain, pancreatic, liver, ovarian, and melanoma. A number of
markers used in cell sorting are emerging as being predictive
of disease progression, indicating that they identify clinically
important cell populations.
Other aspect that was considered in CRC is gene
hypomethylation, which was first described in 1983 by
Feinberg and Vogelstein [32]. Since then, several epigenetic
abnormalities have been reported, mainly in the first stages
of CRC development, while only few have been found
to happen at more advanced stages (adenocarcinoma and
metastasis) [33, 34]. Hypermethylation at gene promoter or
transcription start region has been described to be cause of
gene transcription silencing during CRC development, and
many of the affected genes normally exhibited tumor sup-
pressor roles. In contrast, hypomethylation activates genes
that are normally silenced and results in global chromosomal
instability [35]. Altered acetylation ormethylation of histones
has also been reported in CRC affecting the expression of
tumor-associated genes and cell cycle progression. However,
this epigenetic modification is gene-specific and a general
pattern has not been found. HDAC inhibitors as butyrate,
TSA (Trichostatin A), or SAHA (suberanilohydroxamic acid,
also known as Vorinostat) induce not only hyperacetylation
but also hypermethylation of histones altering the expression
of genes; among them, several ones are involved in tumor
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development and cell cycle and arresting cells in G
1
phase
[36–39]. Some cells may even become resistant to HDAC
inhibitors and develop an overall resistance to different types
of stress enhancing their malignant potential, as has been
described for colon carcinoma cells [40–44]. Additionally, SC
may become CSC under a series of epigenetic and genetic
alterations. Both hypermethylation and hypomethylation of
key genes are involved in epigenetic changes during SCmalig-
nant transformation [35]. Moreover, the fully differentiated
somatic cells can also acquire CSC-characteristics through
massive genetic and epigenetic reprogramming. The CSCs
then give rise to andmaintain the heterogeneous tumor mass
[45].
4. New Players in Gene Expression Regulation:
Noncoding RNAs
4.1. The Discovery of the Noncoding RNAs. In humans, about
2-3% of transcripts have the capacity to encode protein
and approximately 20,000–25,0000 genes encode proteins,
whereas many noncoding elements are transcribed into
noncodingRNA (ncRNA).However, functional ncRNAsmay
arise from only a small fraction of the total genome. These
ncRNAs are a class of RNAmolecules that are involved in the
regulation of biological processes, including gene expression,
epigenetic processes, cell differentiation, proliferation,migra-
tion and apoptosis, and transcriptional and posttranscrip-
tional regulation, and are implicated in different human dis-
eases. Due to the role of ncRNAs in such key processes, they
are a focus of research interest and several excellent reviews
on this topic have been published [9, 46–49]. However, fur-
ther research efforts are necessary to explore the regulatory
functions of this novel class of RNA molecules.
In the 1970s, researchers began to realize that the genome
was transcribed into nonprotein-coding RNAs, as the known
housekeeping ribosomal and transfer RNAs (rRNAs and
tRNAs), and the role of other ncRNAs in gene expression
regulationwas postulated. In the 1980s, small nucleolar RNAs
(snoRNAs; intermediate-sized ncRNAs of 60–300 nt) and
small nuclear RNAs (snRNAs; average length approximately
150 nt) became recognized as major players in posttranscrip-
tional RNA processing. When were ncRNAs first described?
Introns, that were discovered in 1977 [50], accounted for
a part of the noncoding sequences. However, for more
than a decade, researchers paid very little attention to
what happened with the intronic RNA fragments after their
removal from the pre-mRNA. It was not until 1990 that Liu
and Maxwell described that the intronic sequences of the
mouse hsc70 heat shock gene (HSPA8) were the source for
U14 snoRNA [51]. These molecules are primarily involved
in chemical modifications of other RNAs, mainly rRNAs,
tRNAs, and snRNAs. In this process, the complementary
pairing of their guide sequences with that of the RNA target
is essential. There are two main classes of snoRNA, the
C/D box snoRNAs, which are associated with methylation,
and the H/ACA box snoRNAs, which are associated with
pseudouridylation. snoRNAs are components of the small
nucleolar ribonucleoproteins (snoRNPs), which are com-
plexes responsible for the two aforementioned sequence-
specific modifications: 2󸀠-O-methylation and pseudouridyla-
tion. Many of the newly discovered snoRNAs are synthesized
by an intron-processing pathway, which provides a potential
mechanism for coordinating nuclear RNA synthesis. For
example, posttranscriptional modifications of rRNAs take
place in the nucleolus (the nuclear compartment within
which ribosomes are formed) and facilitate rRNA folding and
stability [52].
The functions of ncRNAs are quite variable and specific.
For example, studies on snRNAs have shown that their
primary function is the processing of pre-mRNAs (hetero-
geneous nuclear RNA or hnRNA) in the nucleus. The 7SK-
RNA plays a role in transcription regulation by controlling
the positive transcription elongation factor P-TEFb. It is
found in a small nuclear ribonucleoprotein complex (snRNP)
with a number of other proteins that regulate the stability
and function of the complex. On the other hand, the 7SL-
RNA is a component of the eukaryotic signal recognition
particle together with six distinct polypeptides.The ribozyme
ribonuclease P, that cuts the leader 5󸀠sequences of all tRNAs,
is an example of catalytic RNA. The impact of all of these
topics in which ncRNAs are involved has been reflected in
three Nobel Prizes. In 1989, the Nobel Prize in Chemistry was
awarded jointly to Sidney Altman and Thomas R. Cech “for
their discovery of catalytic properties of RNA.” In 2006, the
Nobel Prize in Physiology or Medicine was awarded jointly
to Andrew Z. Fire and Craig C. Mello “for their discovery of
RNA interference - gene silencing by double-stranded RNA.”
In 2009, the Nobel Prize in Chemistry was awarded jointly
to Venkatraman Ramakrishnan, Thomas A. Steitz, and Ada
E. Yonath “for studies of the structure and function of the
ribosome.”
According to size, the ncRNAs have been systematically
classified into two groups, small ncRNAs (sncRNAs) and
long ncRNAs (lncRNAs), which are shorter than 200 or
longer than 200 nt, respectively.The sncRNAs can be divided
into microRNAs (miRNAs), small interfering RNAs (siR-
NAs), snoRNAs, snRNAs, PIWI-interacting RNAs (piRNAs),
ribozymes, and telomere-associated RNAs (TERC), circular
RNAs (circRNAs), and other sncRNAs. The classification
of lncRNAs is based on different parameters, as genomic
location, effect exerted on DNA sequences, mechanism of
action, and their targeting mechanism [47]. In addition, they
can be classified according to their position in the genome
into intergenic (lincRNA), intronic, bidirectional, sense, and
antisense lncRNAs. Several studies have revealed that both
small and long ncRNAs can regulate gene expression at
the transcriptional, posttranscriptional, and epigenetic lev-
els. Among the former, miRNAs, endogenous siRNAs, and
piRNAs have been described to exert a gene regulation
role. Although only a few lncRNAs have been characterized
to date, recent work has revealed the regulatory role of
lncRNAs. In addition to their length, known lncRNAs have
key differences with small ncRNAs and some intriguing
similarities tomRNAs. Aswe describe later on, small ncRNAs
regulate gene expression by sequence-specific binding, but
lncRNAs do it through diverse mechanisms that remain
unclear [9, 53].
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In 1998, the Nobel Laureates Andrew Fire and Craig
Mello described a key mechanism for controlling the flow
of genetic information. They demonstrated the potent and
specific genetic interference by exogenous double-stranded
RNA in Caenorhabditis elegans, which was more effective in
producing interference than either strand individually [54].
Such effects have been proposed to result from a simple anti-
sense mechanism that depends on hybridization between the
injected RNA and endogenous messenger RNA transcripts.
In this process, gene expression is inhibited by degradation
of specific mRNA molecules. The mechanism underlying
RNA interference and components of the RNA silencing
machinery were identified during the following years. Thus,
two types of sncRNAs, siRNA and miRNA, have attracted
considerable attention because they play an important role
in gene regulation and have a therapeutic potential in the
treatment of many different diseases including cancer [55].
In the last years, growing experimental evidences suggest
that alterations in gene-regulator ncRNAs are relevant in
tumorigenesis and thatmost human tumors are characterized
by dysregulation ofmiRNAs. In this review, we focus onmiR-
NAs, which are considered the main regulatory molecules
among ncRNAs and have been shown to play an important
role in CRC and also in the participation of lncRNAs as well
as circRNAs, both regulating miRNA activity.
4.2. MicroRNAs: The Main Noncoding Regulatory RNAs.
miRNAs are naturally occurring small noncoding, single-
stranded RNA molecules of approximately 22 nucleotides
in length that are derived from hairpin precursors. MiRNA
are well characterized as a large class of gene regulators
and are estimated to regulate the translation of more than
60% of protein-coding genes [9]. They negatively regulate
gene expression by binding to complementary sequences
within target mRNAs for posttranscriptional gene silencing.
This binding occurs mainly within the 3󸀠-untranslated region
(3󸀠UTR) of target mRNA based on sequence complemen-
tarity and results in target mRNA translational repression
or mRNA degradation [56, 57]. In addition, some miRNAs
have been shown to bind to the open reading frame or
to the 5󸀠UTR of the target mRNAs. miRNAs are a class
of highly abundant noncoding RNA molecules that are
involved in several biological processes, as cell proliferation
and differentiation, and in many diseases including cancer.
Since the initial discovery of lin-4 and let-7 miRNAs,
which are components of the gene regulatory network that
controls the timing of larval development in C. elegans, a
plethora of miRNAs has been reported. The association of
miRNAs with cancer development was described for the
first time after the detection of frequent deletions of miR-15
and miR-16 loci in B-cell chronic lymphocytic leukemia [7,
58]. The hallmarks in miRNA discovery and its relationship
with cancer are shown in Table 1. During the last twelve
years, several studies describing the correlations between
miRNA and cancer and metastasis, their role as molecular
biomarkers, and their involvement in the oncogene and
tumor suppressor networks have been published [59].
Sequences and annotations of published miRNAs are
archived in miRBase database.The first release of miRBase in
2002 contained 218 miRNA loci from five species (Table 1).
Since then, the miRNA discovery field has exploded with
hundreds of miRNAs found to be present in each studied
animal and plant genome. They are extended to the majority
of vertebrates and are conserved throughout evolution, from
worms to plants and humans. The number of published
miRNA sequences in miRBase continues to increase rapidly,
mainly driven by small RNA deep sequencing experiments.
Thousands of miRNAs across different species have been
identified; the exponential evolution of the number of pub-
lications along the years is shown in Figure 1(a) as well as
the increase in miRNA entries in the miRBase database and
number of species where they have been found (Figure 1(b)).
The latest version of the miRNA database (release 21; June
2014) contains 28,645 miRNA loci from 223 species and 16
viruses, corresponding at about 35,828 mature miRNAs.This
number is even expanding and mirBase 21 contains at the
moment 1,881 precursors and 2,588 human mature miRNAs
representing 1–3% of all human genes [60].
ThemiRBase also provides rules for the standard nomen-
clature system of the miRNAs and the criteria for identifi-
cation and naming miRNAs (http://www.mirbase.org/help/
nomenclature.shtml) [61, 62]. Thus, the numbering of newly
identified miRNA genes is sequential and each name is
preceded by abbreviated three-letter prefixes to designate
the species; for humans, those letters are “hsa” (Homo
sapiens). The mature sequences are designated as “miR,”
whereas both the gene locus and precursor hairpins (pre-
miRNA) of a miRNA are identified as “mir.” However, names
referring to genomic loci should be written in italics for easier
differentiation from mature sequences. miRNAs with nearly
identical sequences except for one or two nucleotides are
annotated with an additional lowercase letters. For example,
hsa-miR-200b is closely related to hsa-miR-200c (Figures
2(a) and 2(b)). Additionally, miRNAs from genes located in
different genome regions that lead to an identical mature
miRNA are indicated with an additional number (e.g., miR-
135a-1 and miR-135a-2). When both strands of the hairpin
structure of a pre-miRNAare processed asmaturemiRNA, an
indication must be given to specify which arm generates one
or the other of the two miRNAs. Such mature sequences are
named followed by -5p and -3p (e.g.,miR-141-5p andmiR-141-
3p; Figure 2(c)). Finally, when the relative abundancy clearly
indicates which is the predominantly expressed miRNA, the
mature sequences are assigned names of the form miR-56
(the predominant product) and miR-56∗ (from the opposite
arm of the precursor and nonfunctional). However, when
the data are not sufficient to determine which sequence is
the predominant one, or the functionality of a miRNA is
described, names like miR-141-5p (from the 5󸀠 arm) andmiR-
141-3p (from the 3󸀠 arm) are recommended. Finally, attending
to the function of miRNAs, some researchers refer to spe-
cific miRNAs as ts-miRNAs (tumor suppressor), oncomiRs
(oncogenic), and epi-miRNAs (subgroup that modulate the
epigenetic machinery [9]).
Several studies have indicated that miRNAs could be
grouped in “seed families” based on sequence homology at
the 5󸀠 end of the mature miRNA. This 5󸀠 end is crucial
for the stability and proper loading of the miRNA into
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Table 1: Hallmarks in miRNA discovery and its relationship to cancer.
Year Hallmark
1993
The first regulatory noncoding RNA was identified: lin-4
Two discoveries identified a novel mechanism of posttranscriptional gene regulation. The first miRNA lin-4 was described in
1993 as asmall temporal RNA (stRNA) in the laboratory of Ambros working with the nematode Caenorhabditis elegans. In this
system, the transition from the first to the second larval stage fates requires the 22-nucleotide lin-4 RNA. The gene lin-4
encodes a small RNA, which is a non-protein-coding regulatory RNAmolecule. In the same issue of cell, the group of Ruvkun
reported the first miRNA target gene, the heterochronic gene lin-14, that is regulated by lin-4 mediating the temporal pattern
formation in C. elegans. The sequence of lin-4 has antisense complementarity to lin-14 mRNA that encodes lin-14 protein
[80, 81].
2000
The second small temporal RNA and the first in humans was identified: let-7
Seven years later the second regulatory stRNA, let-7, was discovered. The transition from late larval to adult cell fates in C.
elegans requires the 21-nucleotide let-7 RNA. This stRNA negatively regulates, among others, lin-14 and lin-28 through
RNA-RNA interactions with their 3󸀠 untranslated regions. The sequential stage-specific expression of the lin-4 and let-7 RNAs
regulates the timing of C. elegans development. The let-7 RNA showed its conservation across species, includingH. sapiens. In
humans, let-7 was detected at different expression levels in several tissues, including brain, heart, kidney, liver, lung, trachea,
colon, small intestine, spleen, stomach, and thymus [82, 83].
2001
The term miRNA is introduced
In addition to lin-4 and let-7, several stRNAs with regulatory functions were discovered using bioinformatics and cDNA
cloning. Three papers published in the same issue of Science showed the existence of small RNAs involved in
posttranscriptional regulation of target mRNA in vertebrates and invertebrates. These RNAs were named microRNAs
(miRNA) to refer to this class of small regulatory RNAs [84–86].
2002
miRNA is associated with cancer
The relevance of miRNAs to cancer was suggested by changes in their expression patterns and recurrent amplification and
deletion of miRNA genes in tumors. The first report suggesting a role of miRNAs in cancer described a frequent 13q14 deletion
that encoded the miRNA-15a/16-1 cluster reducing its expression in chronic lymphocytic leukemia. Both genes were deleted
or downregulated in 68% of analyzed cases. Two years later, the same group found that a significant percentage of miRNAs is
located at fragile sites and in genomic regions altered in cancers, including regions of amplification or loss of heterozygosity or
breakpoints. They suggested that miRNAs were a new class of genes with a relevant role in human cancer pathogenesis [7, 58].
2003
miRNAs in colorectal cancer
A total of 28 different miRNA sequences were identified in a colonic adenocarcinoma and normal mucosa. Among them,
miR-21, miR-143, miR-145, and miR-200c were expressed. In colorectal cancer, two different miRNAs, miR-143 and miR-145
exhibited significantly reduced levels of the mature miRNAs compared to normal mucosa specimens. The maintenance of
constant levels of unprocessed hairpin precursors in both normal and tumor tissues suggested that altered transcription is not
responsible for reduced miRNA levels. Authors proposed that the reduction is due to posttranscriptional processes such as a
reduced Dicer-processing activity in the neoplastic cells or reduced stability of these specific miRNAs [87].
2002-2003
miRBase: the miRNA sequence database
miRBase was established in 2002 as a miRNA registry. The criteria for the identification of miRNAs was published in 2003.
The miRBase grew from the miRNA registry resource set up by Griffiths-Jones in 2003 and is the public repository for all
published miRNA sequences and annotation data. Its aim is assigning stable and consistent names to newly discovered
miRNAs. The first release of miRBase in 2002 contained 218 miRNA loci from five species. Since then, the number of miRNAs
discovered has increased exponentially. The miRBase is freely available at http://www.mirbase.org/ [60–62].
2004
miRNAs as molecular biomarkers
let-7 expression is associated with survival of lung cancer patients. This was the first time that miRNAs are suggested as
prognostic markers. The article described that let-7 expression was reduced in lung cancers and that lung cancer patients with
low let-7 expression levels had a significantly shorter survival after potentially curative resection. Currently, the clinical utility
of miRNAs as diagnostic/prognostic biomarkers has been demonstrated in several types of cancer by numerous studies using
tumor samples [88].
2005
Function of miRNAs in cancer
The first reports addressing the biological function of miRNAs in cancer were published. These articles described that miR-15
and miR-16, the first two miRNAs associated with cancer, play a role in apoptosis regulation by targeting the antiapoptotic
bcl-2 mRNA.They also reported the first miRNA-target interaction with relevance to cancer: human Ras expression is
regulated by let-7 in cell culture. In fact, let-7 expression is decreased in lung cancer compared with normal tissue, and it
correlates with the increased Ras protein levels detected in lung tumor samples. Since then, hundreds of publications have
reported on the role of miRNAs in tumors [89–91].
2005
The expression of miRNAs is regulated by transcription factors
It is described that c-Myc activates the expression of a cluster of six miRNAs on human chromosome 13. In turn, the
expression of a target of c-Myc, the transcription factor E2F1, is negatively regulated by two oncogenic miRNAs in this cluster,
miR-17-5p and miR-20a [92].
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Table 1: Continued.
Year Hallmark
2005–2007
Role of miRNAs as candidate components of oncogene and tumor-suppressor networks
The role of miRNAs as oncogenes (oncomiRs) or tumor suppressors involved in a variety of pathways deregulated in cancer
was reported. The polycistronic miRNA cluster miR-17-92, located in a region of DNA that is amplified in human B-cell
lymphomas, is reported as a potential human oncogene. Other studies, using different types of tumors,also described the role
of miR-143, miR-145, miR-372, miR-373, and miR-155/BIC as oncogenic miRNAs. Conversely, five independent reports
describe that the miR-34 family of evolutionarily conserved miRNAs are directly induced by p53 in response to DNA damage
and oncogenic stress. miR-34a was identified as a miRNA component of the p53 network, revealing an interplay between
proteins and noncoding RNAs in a tumor-suppressor pathway [93–102].
2007
miRNAs “sponges”
The initial term “target mimicry” was coined in plants to define the mechanism of inhibition of miRNA activity discovered
studying the phosphate homeostasis in Arabidopsis thaliana. In the same year, there is a report in humans on specific
competitive inhibitors from transcripts expressed from strong promoters that contain multiple tandem binding sites to several
miRNA seed families; they were named “miRNA sponges” [103, 104].
2007–2009
miRNAs and metastasis
miRNAs are also involved in metastasis; they can promote or inhibit metastasis. The first miRNA described as a metastasis
activator was miR-10b, that positively regulates cell migration and invasion in vitro and is capable of initiating tumor invasion
and metastasis in vivo. Expression levels of miR-10b in primary breast carcinomas correlate with clinical progression. Its
expression is elevated in about 50% of metastatic breast tumors compared with metastasis-free tumors or normal breast
tissues. Human miR-373 and miR-520c also stimulate cancer cell migration and invasion in vitro and in vivo. On the contrary,
other miRNAs can prevent tumor metastasis. Breast cancer patients with low expression levels of miR-335, miR-126, and
miR-206 had a shorter median time to metastatic relapse. Restoration of their expression in breast cancer cell lines decreased
the number of metastases in inoculated mice [105–108].
2008
Circulating miRNA biomarkers
miRNAs are detected in blood samples (plasma, platelets, erythrocytes, and nucleated blood cells). This pointed out that
endogenous plasma miRNAs are protected in some manner to prevent their degradation. Due to their stability in the
circulation, miRNAs began to be considered for their potential use as biomarkers for different pathologies [109–112].
2013
miRNA therapeutics
miR-34a mimic (MRX34) enters Phase 1 clinical study in liver cancer and other solid tumors with liver involvement, as well as
hematological malignancies. Regretfully, this study was halted in 2016 due to immune-related serious adverse events [113].
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Figure 1: Evolution of the number of publications on miRNAs and lncRNAs. (a)The number of publications per year (searched in PubMed)
that contain the terms “microRNA” (black bars) and “microRNA + cancer” (empty bars) in their title, abstract, or keywords, is shown. The
inset is equivalent with the terms “lncRNA” and “lncRNA + cancer”. (b) Evolution of the number of entries in miRBase fromDecember 2002
until the last release (release 21) I June 2014. The inset shows the increase in the number of species where miRNAs have been found.
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Figure 2: Interaction betweenmiRNAs and targetmRNAs in animals andmiRNA-200 family. (a)miRNAs (green) targetmRNAs (blue) in the
3󸀠UTR.ThismRNA region can bind one or variousmiRISC complexes arising from the same or differentmiRNAs. A perfect complementarity
is found in the seed region between nucleotides 2 and 7 from the 5󸀠 end of the miRNA (orange box). A central bulge prevents endonucleolytic
cleavage mediated by Ago2 (a major difference with the miRNA-target mRNA interaction in plants). A few nucleotide matches in the miRNA
3󸀠 end (especially between nucleotides 13 and 16; yellowbox) are necessary for the best stabilization of themiRNA/mRNAduplex.Thepresence
in themRNA sequence of anA residue in position 1 and/or anA orU residue in position 9 can increasemiRNA efficiency [6]. (b)ThemiR-200
family of miRNAs consists of two closely related subfamilies that differ in one nucleotide within the seed sequence (boxed).The five miR-200
family members are located on two different genetic loci in chromosomes 1 and 12. (c) Schematic representation of the secondary structure
of the pre-miR-141 hairpin. The sequence of the mature miR-141-3p is indicated in red and the miR-141-5p (previously called miR-141∗) is in
blue. Black triangles show Dicer cleavage sites due to its RNase III activity.
the miRNA-associated multiprotein RNA-induced silencing
complex (miRISC). A schematic model of one of the canoni-
cal interactions between miRNAs and 3󸀠UTR target mRNAs
is shown in Figure 2(a). A perfect complementarity is found
primarily in the seed region between nucleotides 2 and 7
from the 5󸀠 end of the miRNA. A few nucleotide matches
in the miRNA 3󸀠 end (nucleotides 13 to 16) are necessary for
the best stabilization of the miRNA/mRNA target duplex [6].
Other categories of target sites, as marginal or atypical sites,
have also been reported according to their structural features.
Therefore, the targets of a miRNA family are likely to overlap
amongmembers. In addition, a single mRNA can be targeted
by multiple miRNAs, and an individual miRNA can have
more than one mRNA target. Those mRNAs that share the
same miRNA response elements, or bind members from the
same miRNA family, are reported to influence the expression
of each other by competing formiRNAbinding. Interestingly,
the mRNA-miRNA interaction network is complex; single
miRNA might regulate and bind to as many as two hundred
mRNA targets. The proteins corresponding to these targets
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can be diverse in their function; they include transcription
factors, secreted factors, receptors, and transporters [63].The
chromosomal localization and seed sequences correspond-
ing to the miR-200 family members, which comprise five
miRNAs, miR-200a, -200b, -200c, miR-141, and miR-429, are
shown in Figure 2(b). The secondary structure of the pre-
miR-141 hairpin and the origin and sequences of miR-141-5p
and miR-141-3p are presented in Figure 2(c).
4.3. MicroRNA Biogenesis. Eukaryotic nuclear DNA encodes
miRNAs and their genomic organization is diverse. They can
be located within exons or introns, in intergenic sequences
or produced from lariat introns [64, 65]. Exonic miRNAs are
located within exons and are independently transcribed from
their ownpromoters into precursor pri-miRNAs.When some
miRNA genes overlap protein-coding genes in the antisense
direction, they also have their own promoters. Inmammalian
cells,more than 50%ofmiRNAs are foundwithin an intron of
a protein-coding gene.Theymay be under the control of their
own independent promoter or may be cotranscribed with
the host gene and processed into pre-miRNAs subsequent to
intron splicing. In addition, some miRNA genes are inter-
genic and their transcription is driven by their own upstream
promoter and may be either RNA polymerase II-dependent
or III-dependent. Moreover, mirtrons are small lariat intron-
derived precursor miRNAs excised by the splicing machin-
ery. Following splicing, mirtrons undergo debranching by
a lariat-debranching enzyme and then fold into hairpin
structures resembling precursormiRNAs.Mirtrons are trans-
ported to the cytoplasm by exportin-5/Ran-GTP following
the typical miRNA-processing pathway presented below.
Additionally, an individual pri-miRNA can either produce a
single miRNA or contain clusters of two or more miRNAs
that are processed from a long primary transcriptional unit.
In this way, the largest gene cluster of human miRNAs
is located in chromosome 19q13.41. This miRNA cluster
(C19MC) encodesmore than 59 mature microRNAs and is
exclusively expressed in the placenta and in undifferentiated
cells [66].
Biogenesis of miRNAs takes place through a multistep
process that involves the activity of RNase III enzymes
Drosha and Dicer and ultimately results in the production of
mature miRNAs of about 22 nt. Several review articles sum-
marize the miRNA biogenesis and its regulation [10–12, 65,
67–69].ThemiRNA biogenesis pathway is shown in Figure 3.
The process generally starts with the transcription by RNA
polymerase II of the miRNA gene yielding in the nucleus
primary large miRNA (pri-miRNA) transcripts which are
5󸀠capped (m7GpppG) and 3󸀠polyadenylated [poly(A) tail].
These long pri-miRNA transcripts are subjected to process-
ing by the microprocessor double-stranded RNA (dsRNA)
RNase III enzyme Drosha and its cofactor the dsRNA-
binding protein DGCR8 (DiGeorge syndrome critical region
8). Drosha recognizes the base of the stem-loop hairpin
structure and cleaves the 5󸀠 and 3󸀠 arms of the pri-miRNA,
whereas DGCR8 directly interacts with and stabilizes the
pri-miRNA and determines the precise cleavage site. Fol-
lowing cleavage of the pri-miRNA molecule by the Drosha
microprocessor, its size is reduced to a 60–70 nt pre-miRNA
precursor product (pre-miRNA)which contains an imperfect
stem-loop hairpin flanked by single-stranded RNA (ssRNA).
After nuclear processing, the pre-miRNAs are then exported
from the nucleus into cytoplasm by exportin-5/Ran-GTP, a
nuclear transport receptor complex. Dicer, another RNase
III enzyme, and the transactivation-responsive RNA-binding
protein (TRBP or TARBP2) process the pre-miRNA in the
cytoplasm to generate a transient ∼22 nt miRNA:miRNA∗
duplex with 2 nt overhangs at the 3󸀠 ends. Next, the RISC
loading complex is formed after recruiting Argonaute (AGO)
protein. One miRNA strand is the antisense or guide/mature
strand, while miRNA∗ is the sense or passenger strand. This
duplex is then loaded into the miRISC, which includes an
AGO2 protein, GW182/TNRC6 proteins, Gemin 3/4 (Dead-
box helicases DDX20 and DDX42), among other potential
proteins, and the mature functional guide single-stranded
miRNA yielding a functional miRISC. Usually the passenger
strand is cleaved. The mature functional miRNA guides the
RNA-induced silencing complex (RISC) to miRNA response
elements on targetmRNA transcripts to posttranscriptionally
negatively regulate gene expression via translation inhibition
or transcript degradation [57].
An exception to this general pathway is the maturation
of mirtrons. Figure 3 shows that mRNA splicing can produce
miRNA-containing introns that are processed by a Drosha-
independent mechanism. The lariat intron is debranched
by a lariat-debranching enzyme instead of Drosha and,
after refolding into hairpin structures, is transported to the
cytoplasm by exportin-5/Ran-GTP and follows the typical
miRNA-processing pathway. Thus, they are cleaved by Dicer
and themature strands are loaded ontomiRISC. Figure 3 also
shows the incorporation of the siRNAs into the RNA silenc-
ingmachinery at the level of Dicer.The complex regulation of
miRNA gene transcription as well as the multiple regulators
(activators and repressors) of the miRNAs processing have
been considered in several reviews [10, 12, 68].
miRNAs regulate gene expression throughmultiple path-
ways in a sequence-specific fashion. As we have already
described, the degree of complementarity between the 5󸀠seed
region of themiRNA and its 3󸀠UTR target mRNAdetermines
the process (Figure 2(a)). In plants, the perfect or near-perfect
base pairing often leads to the cleavage of target mRNAs and
subsequent gene silencing by RNA interference pathway. In
eukaryotic cells, also a perfect pairing between a miRNA
and its target site induces endonucleolytic cleavage by Arg-
onaute, leading to rapid degradation of the mRNA. However,
the binding of miRNAs to mRNA targets with imperfect
complementarity block target gene expression at the level
of protein translation [12, 15, 65, 68]. In eukaryotic cells,
mRNA translation is stimulated by the formation of circular
structures where the 5󸀠 and 3󸀠 ends of mRNAs are connected
through the interaction between a complex formed by the
eukaryotic initiation factor eIF-4E, that binds the 5󸀠cap, and
the cytoplasmic poly(A)-binding protein (PABPC), brought
together by eiF-4G. The latter also interacts with eiF-3,
which binds the 40S ribosomal subunit and promotes its
assembly on the mRNA (Figure 4). The partial pairing of
the miRNA complex to target 3󸀠UTR sites can result in
deadenylation of the mRNA through recruitment of the
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CCR4–NOTor PAN2/3 complexes by themiRISC-associated
GW182 proteins. Loss of the poly(A) tail causes dissociation
of PABPC and leads to mRNA degradation. Moreover, the
miRISC can also induce translational repression by blocking
initiation via recruitment of CCR4–NOT by GW182. The
translational repression can also be induced by themiRISC by
inhibiting a step after initiation, such as promoting ribosome
drop-off or stimulating proteolysis of the nascent peptide.
In cancer, changes in specific oncogenic and tumor sup-
pressor miRNAs, as well as alterations in the miRNA expres-
sion profile in human tumors, have been shown to play a key
role in the development of cancer. For example, let-7 family
of miRNAs is downregulated in several types of cancer and is
associated with poor patient outcomes [70]. However, several
studies have established that mature miRNA accumulation
also occurs after transcription being involved mechanisms of
posttranscriptional regulation [67]. Alterations in themiRNA
biogenesis pathway can also have an important role in cancer
progression. In fact, it has been reported that mutations
in the miRNA-processing machinery and dysregulation of
miRNA biogenesis pathway are implicated in the pathogene-
sis of human disorders, including cancer [11]. Moreover, the
core biogenesis machinery components, including Drosha,
DGCR8, DICER1, and TRBP, are subject to posttranslational
control such as phosphorylation and/or acetylation (reviewed
in [10]). All of these dysfunctions in components of the
miRNA biogenesis pathway produce expression changes in
a large number of cellular miRNAs which can be correlated
with poor patient outcomes [71–73].
Several genetic defects in components of the miRNA-
processing machinery have been reported in cancer. Muta-
tions in genes that encode DROSHA, DGRC8, TARBP2,
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DICER1, and XPO5 (exportin 5) point out the relevance of
the miRNA biogenesis pathways in cellular transformation
[9, 11, 13, 14, 74, 75]. For example, the export of pre-miRNAs
into the cytoplasm is mediated by the exportin 5/Ran-
GTP complex. XPO5-inactivating mutations were identified
in sporadic colon, gastric, and endometrial tumors with
microsatellite instability. These XPO5 mutations impair pre-
miRNA export to the cytoplasm and result in an accumu-
lation of pre-miRNAs in the nucleus, leading to defects in
miRNA biogenesis [75].
Alterations in the expression of components of the
miRNA machinery are also involved in CRC. Kim and
coworkers [76] analyzed the mRNA expressions of DGCR8
and AGO2 in 60 CRC tissues and adjacent histologically
nonneoplastic tissues by using quantitative real-time PCR.
They found that whereas mRNA expression level of DGCR8
is upregulated in CRC, the expression of AGO2 mRNA was
not significantly altered in CRC tissues. Other studies using
237 samples from colorectal adenocarcinomas withmoderate
differentiation showed that a direct correlation betweenDicer
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upregulation and poor prognosis in patients with CRC as
also occurs on prostate cancer. On the contrary, in breast,
lung, and ovary cancer, Dicer has been shown to be a marker
of good prognosis [77]. It has also been reported that an
increased expression of DicermRNA in normalmucosa from
CRC patients is significantly related to poor survival inde-
pendently of gender, age, tumor site, stage, and differentiation
[78]. Finally, a study on the expression of Drosha, Dicer, and
Ago2mRNAs and protein in three colon cancer cell lines and
in human CRC samples revealed that they were present in
all the samples analyzed and the authors suggested that they
were possibly implicated in CRC pathobiology. mRNA levels
of Dicer were significantly augmented in stage III compared
to stage II tumors suggesting that Dicer might have a role in
the progression of these tumors to advanced stages [79].
5. Noncoding RNAs and Their Involvement in
Colorectal Cancer
5.1. MicroRNAs and Colorectal Cancer. miRNAs are critical
regulators of gene expression and an altered expression of
miRNAs has been shown to be associated with various
types of cancer. Figure 1(a) shows the increasing number of
publications dealing with the relationship between miRNAs
and cancer. More than 50% of humanmiRNA genes are often
located in specific chromosomal regions prone to damage
through deletion, amplification, or translocation, which may
result in malignant transformation [7]. Cancer development
can also arise from dysregulation of miRNA biogenesis path-
way [74]. In the context of cancer, miRNAs may have onco-
genic or tumor-suppressive roles according to the effect they
have on pathways leading to tumor development. Oncogenic
miRNAs, or oncomiRs, target and downregulate endogenous
tumor suppressor genes, whereas tumor suppressor miRNAs
play an important role in downregulating genes associated
with growth and metastasis. Thus, overexpression, genetic
amplification, and gain-of-function mutations of oncogenic
miRNAs as well as genetic deletion and loss-of-function
mutations of tumor suppressor miRNAs are linked to human
cancer. Furthermore, global miRNA depletion caused by
genetic and epigenetic alterations, dysregulation of com-
ponents of the miRNA biogenesis machinery, or changes
in global miRNA levels resulting from a defective miRNA
biogenesis pathway play critical roles in the pathogenesis of
human disorders, including cancer [11, 74, 220].
In CRC, some miRNAs are abnormally downregulated
or upregulated; thus they may act as tumor suppressor or
as oncogenes in tumor development. In addition, miRNA
expression patterns have been suggested as predictive prog-
nosis markers in CRC and support diagnosis of poorly dif-
ferentiated tumors.The involvement of oncogenic and tumor
suppressor miRNAs in key signaling pathways in CRC, their
inductors, and targets, as well as the changes in the expression
of some of them in the transition fromnormal colonmucosa-
adenoma-carcinoma-advanced carcinoma, have been also
described in many different review articles [47, 221–230]. An
overview of some oncogenic and tumor suppressor miRNAs
involved in CRC, their role in CRC, and the verified targets is
shown in Table 2.
Accumulating evidence strongly indicates that aberrant
miRNA expression is an important feature of CRC. The
first association between miRNAs and CRC was described
by Michael and coworkers in 2003 [87], using CRC tis-
sue compared to healthy tissue (Table 1). Several miRNA
sequences were identified, among them miR-21, miR-143,
miR-145, and miR-200c. miR-143 and miR-145 exhibited
significantly reduced levels of the fully processed miRNA
in tumors compared to normal specimens. On the other
hand, the first study that evaluated the association between
miRNA expression patterns and CRC prognosis or therapeu-
tic outcome was carried out by Schetter and coworkers [231].
miRNAmicroarray expression profiling of tumors and paired
nontumor tissues was performed on a US test cohort of 84
patients with CRC, evaluating associations with tumor status,
TNM staging, survival prognosis, and response to adjuvant
chemotherapy. Associations were validated in a second,
independent Chinese cohort of 113 patients using quantitative
reverse transcription PCR assays. They identified 5 miRNAs
which were significantly altered in CRC. In particular, miR-
21 was overexpressed in 87% of colon cancers specimens and
higher miR-21 expression correlated with poorer outcome.
Several studies have described the differentially expressed
miRNAs in CRC. Wu and coworkers [232] measured the dif-
ferential expression ofmiRNAs in colorectal adenocarcinoma
tissues from 28 patients and analyzed their profiles at various
differentiation stages. This study compared the expression
level of 1547 miRNAs using qRT-PCR. Among them, 93
were found to be significantly dysregulated in colorectal
adenocarcinoma relative to normal tissues. In particular,
miR-1, miR-145, and miR-145∗ were downregulated more
than tenfold and were suggested as potential biomarkers
for CRC diagnosis. Furthermore, 58 miRNAs demonstrated
significantly altered expression between well and moderately
differentiated cancers, and 32 could be used to distinguish
normal from cancerous tissues, as well as different levels
of differentiation. In other study, microarrays were used to
profile the expression of 315 human miRNAs in 10 normal
mucosa samples and 49 stage II colon cancers differing with
regard to microsatellite status and recurrence of disease.
Several miRNAs were differentially expressed between nor-
mal tissue and tumor microsatellite subtypes, with miR-145
showing the lowest expression in cancer relative to normal
tissue. Functional studies also showed that miR-145 potently
suppressed growth of different colon carcinoma cell lines
(LS174T, HCT116, and DLD1 cells) [233].
Hamfjord and coworkers [234] performed a global anal-
ysis of dysregulated miRNAs in paired samples of normal
mucosa and tumor from eight patients with CRC. In this
study, the normal and adjacent tumor tissue samples were
paired, thus taking into account the baseline differences
between individuals when testing for differential expression.
At least, 37miRNAswere identified as differentially expressed
between the matched pairs of CRC tissues and normal colon
mucosa, 19 downregulated and 18 upregulated. Some of these
miRNAs were previously published as potential regulators
in colorectal adenocarcinomas, such as miR-1, miR-96, and
miR-145. They discovered 16 dysregulated miRNAs, which
were not previously associatedwith colorectal carcinogenesis.
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Table 2: Oncogenic and tumor suppressor miRNAs involved in colorectal cancer.
miRNA Verified targets Role in colorectal cancer References
Oncogenic miRNAs (upregulated)
miR-18a ATM Blocking apoptosis, DNA repair, and sensitivity toetoposide [114]
miR-21 PTEN, PCDC4, TGFBR2, CDC25A Proliferation, apoptosis, invasion, migration, CSCmaintenance [115–117]
miR-29a KLF4 Invasion, metastasis [118]
miR-31 HIF1A, RhoBTB1, RASA1 Proliferation, migration, invasion, tumor growth [119–121]
miR-32 PTEN Proliferation, migration, invasion, apoptosis [122]
miR-92a PTEN Proliferation, migration, invasion, apoptosis, EMT [123]
miR-95 SNX1 Proliferation, tumor growth [124]
miR-96 TP53INP1, FOXO1, FOXO3A Proliferation [125]
miR-103 DICER, PTEN Proliferation, migration, tumor growth [126]
miR-135a/b APC Proliferation [127]
miR-155 MLH1, MSH2, MSH6 Altering DNA damage response [128]
miR-181a WIF-1, PTEN Proliferation, migration, invasion, tumor growth, livermetastasis, metabolic shift, EMT [129, 130]
miR-182 FOXF2 Cell growth, invasion, increased 𝛽-catenin activity [131]
miR-196b FAS Blocking apoptosis [132]
miR-214 PTEN, PDLIM2 Inflammation [133]
miR-223 RASA1 Tumor growth [134]
miR-224 SMAD4 Metastasis [135]
Tumor suppressor miRNAs (downregulated)
let-7 KRAS Proliferation [91]
miR-7 EGFR, RAF1 Proliferation [136]
miR-18a∗ KRAS Proliferation [137]
miR-26b TAF12, PTP4A1, CHFR, ALS2CR2 Proliferation, apoptosis, invasion, migration [138]
miR-27b VEDFC Proliferation, angiogenesis [139]
miR-34a SIRT1 Apoptosis [140]
miR-100 RAP1B Proliferation, invasion, apoptosis [141]
miR-101 SPHK1 Angiogenesis [142]
miR-124 STAT3 Proliferation, apoptosis, tumor growth, differentiation [143]
miR-126 VEGFA, IRS-1, CXCR4 Proliferation, migration, invasion, cell cycle arrest,angiogenesis [144–146]
miR-133a FSCN1, LASP1 Proliferation, invasion, migration, tumor growth,metastasis, phosphorylation of ERK/MEK [147, 148]
miR-133b TBPL1, CXCR4 Proliferation, invasion, migration, apoptosis [149, 150]
miR-139 IGF1R, NOTCH1 Proliferation, migration, invasion, apoptosis, tumorgrowth, cell cycle arrest [151, 152]
miR-143 ERK5, KRAS, IGF1R Proliferation [153, 154]
miR-144 MTOR Proliferation [155]
miR-145 IRS1, NRAS, IGF1R Proliferation, invasion, migration, angiogenesis, tumorgrowth, metastasis [153, 154, 156]
miR-148b CCK2R, PIK3R3 Proliferation, tumor growth, tumor size [157, 158]
miR-194 PDK1, AKT2, XIAP, MAP4K4
Proliferation, apoptosis, migration, angiogenesis, cell
cycle arrest, tumor growth and size, differentiation,
metastasis
[159, 160]
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Table 2: Continued.
miRNA Verified targets Role in colorectal cancer References
miR-195 BCL2 Apoptosis [161]
miR-200a/c ZEB1/2 EMT [87, 162]
miR-206 NOTCH3 Proliferation, migration, apoptosis, cell cycle arrest [163]
miR-214 FGFR1 Proliferation, migration, invasion, tumor growth,metastasis [164]
miR-218 BMI1 Proliferation, apoptosis, cell cycle arrest [165]
miR-224 CDC42 Migration [166]
miR-320a CTNNB1, RAC1 Proliferation, migration, invasion, cell cycle arrest [167, 168]
miR-342 DNMT1 Proliferation, invasion, cell cycle arrest, tumor growth,metastasis [169]
miR-365 BCL2, CCND1 Apoptosis [170]
miR-375 PIK3CA Proliferation, cell cycle arrest, tumor growth [171]
miR-378 VIM Proliferation, invasion, tumor growth and size,metastasis [172]
miR-429 ONECUT2 Migration, invasion, EMT [173]
miR-455 RAF1 Proliferation, invasion [174]
miR-491 BCLXL Apoptosis [175]
miR-638 SOX2 Invasion, migration, EMT [176]
The downregulated ones were miR-490-3p, miR-628-3p and
miR-628-5p, miR-1297, miR-3151, miR-3163, miR-3622a-5p,
and miR-3656 and the upregulated miR-105, miR-549, miR-
1269, miR-1827, miR-3144-3p, miR-3177, miR-3180-3p, and
miR-4326.On the other hand, a genemodule-based approach
to inferring key miRNAs regulating the major gene network
alterations in CRC has been proposed comparing 90 normal
and 107CRC samples in total. Among the inferred candidates,
threemiRNAs,miR-101,miR-124, andmiR-139, are frequently
downregulated in CRC tumors. Computational and exper-
imental analyses demonstrate that miR-139 can inhibit cell
proliferation and cell cycle G1/S transition. In addition, miR-
139 was found to be significantly downregulated in early
pathological cancer stages and its expression remained at very
low levels in advanced stages. MiR-139 was determined to be
a key tumor suppressor in early cancer development [235].
Dysregulation in circulating blood miRNAs is reflective of
those in colorectal tissues; in fact, a triple miRNA classifier
consisting in miR-193a-3p, miR-23a, and miR-338-5p has
been suggested as a potential blood biomarker for early
detection of CRC [236].
5.2. Signaling Pathways in Colorectal Cancer Regulated by
miRNAs. Considering the classic multistep colorectal car-
cinogenesismodel proposed by Fearon andVogelstein in 1990
[20], most CRCs progress through the sequential accumula-
tion of molecular alterations associated with the adenoma-
to-carcinoma progression. Dysregulation of a significant
number of miRNAs in CRC and colon CSCs has been
described in the literature [47, 221, 225, 237, 238] but special
attention has been directed towards those miRNAs involved
in signaling pathways and cellular processes. Among the
signaling pathways that are modified in CRC carcinogenesis
are those that result in activation of prosurvival, propro-
liferative, and metastasis (i.e., Wnt, EGFR, and TGF-𝛽) as
well as impairment of p53 function [34, 226]. Extensive
studies evidence that miRNAs can regulate all the major
pathways in CRC; briefly, this includes their impact on 𝛽-
catenin/Wnt signaling (miR-135a/b, miR-139, miR-145, miR-
17-92), proliferation (let-7 family, miR-18a, miR-21, miR-126,
miR-143, miR-200c), apoptosis (miR-34a, miR-133b, miR-
195), cell cycle control (miR- 34a, miR-192, miR-215, miR-
675), p53 signaling (miR-34b/c), differentiation (miR-141,
miR-200c), and migration and invasion (miR-126, miR-143,
miR-196a, miR-200a/b/c, miR-373, miR-520c) [34].
Wnt activation signaling pathway is crucial for the reg-
ulation of stem cell activity to the intestinal crypt base and
for the renewal of the epithelial cells. Activation of Wnt
signaling induces cell survival and inhibits cell death and
differentiation.Themutation of the tumor suppressor APC is
one of the first events for the initiation of colorectal neoplasia.
A miRNA-mediated mechanism has been described in CRC
to control the expression of the APC gene and consequent
activation of theWnt signaling pathway. In adenocarcinomas,
as well as premalignant colorectal adenomas, oncomiRsmiR-
135a and miR-135b are overexpressed and directly target the
3󸀠UTR of the APC mRNA, suppress the APC expression,
and activate Wnt signaling [127]. In addition, several Wnt-
pathway genes contain binding sites in the 3󸀠UTR of their
corresponding mRNAs for members of the miR-34 family.
The miR-34 family comprises three processed miRNAs that
are encoded by two different genetic loci. MiR-34a is encoded
by one transcript, and miR-34b and miR-34c arise from
a common primary transcript. The members of the miR-
34 family are direct p53 targets, which induce apoptosis,
cell cycle arrest, and senescence [239]. 𝛽-Catenin binds to
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members of the TCF/LEF family of transcription factors
whose activity is mainly regulated by the miR-34 family.
In this way, miR-34 represses the activity of the TCF/LEF
complex and establishes a relationship between the Wnt sig-
naling pathway and p53 activity. Loss of p53 functions causes
increased activity of Wnt signaling cascade and promotes
the Snail-dependent EMT. Moreover, higher expression of
oncogenic miR-21 in adenomas and CRC relative to normal
tissues suggests that abnormal expression of this miRNA
is an early event in the progression towards CRC. It has
also been reported that miR-21 promotes cell migration and
invasion by targeting the PDCD4 (Programmed Cell Death
Protein 4) and PTEN (phosphatase and tensin homolog)
tumor suppressor genes [115, 116].
In early stages of cell transformation in CRC, an upregu-
lation ofmiR-17-92 cluster has been detected. PTEN and E2Fs
mRNAs were among the first validated miR-17-92 targets.
Recently, Li and coworkers [240] have demonstrated a direct
link between APC and the miR-17-92 cluster. APC represses
miR-17-92 through inhibition of 𝛽-catenin. Mutation of APC
leads to stabilization of 𝛽-catenin, which in turn binds to and
activates the miR-17-92 promoter. Moreover, elevated level
of 𝛽-catenin is significantly correlated with miR-19a (that
belongs to the miR-17-92 family) overexpression in CRC.
miRNAs have been reported to regulate the stemness
of colon CSCs mainly via regulation of important signal-
ing pathways as Wnt/𝛽-catenin and Notch, acting also on
processes that involve CSCs altering the expression of cell
cycle and EMT-related genes. Notch and Wnt pathways are
involved in crypt development and in proliferation and self-
renewal of colon SCs, decreasing apoptosis; these pathways
are commonly upregulated in SC populations of colon cancer
tissue. The most frequently reported miRNAs involved in
the regulation of colon CSCs are miR-21 and miR-34a
through modifications in the Wnt/𝛽-catenin and Notch/C-
kit-Erk pathways, respectively. miRNA-21 is overexpressed in
colon CSCs and is able to downregulate the expression of
TGFBR2 gene (TGF-𝛽 receptor II), resulting in activation of
the Wnt/𝛽-catenin pathway and consequent increase in the
expression of downstream target genes as c-Myc and cyclin-
D1 [117]. miR-21 also targets PTEN reducing its expression
and with a concomitant activation of Akt signaling pathway,
thus increasing the tumorigenic properties of colonic CSCs
[241]. Finally, miR-21 can also control the expression of other
miRNA, miR-145 and, in turn, increase the expression and
activity of intact K-Ras in colon CSCs [242]. miR-34a is
downregulated in colonic CSCs and restoration of its expres-
sion leads to differentiation of CSCs derived from colon
cancer tissue to non-CSCs. miR-34a targets Notch signaling
pathway, that plays an important role in symmetrical and
asymmetrical cell division of stem cells.Moreover, c-kit (stem
cell factor receptor) is a direct mRNA target of miR-34a; thus,
downregulation of miR-34a leads to overexpression of c-kit
and activation of several stemness markers [238].
The epidermal growth factor receptor (EGFR) signal-
ing pathway is also involved in the development of CRC.
EGFR can activate different signal transduction pathways as
Ras/MAPK and the phosphatidylinositide 3 kinase- (PI3K-
) Akt pathways. Activating K-Ras mutations have been
described to induce activation of various downstream effec-
tors that mediate tumor growth, survival, and metastasis in
many cancers [34, 226]. In CRC, tumor suppressors, miR-
143 and miR-145, that are located on chromosome 5, are
reduced. Downregulated expression of miR-143 and miR-
145 has been described to target multiple mRNAs related to
the MAPK signaling pathway, including K-Ras, ERK5, IRS-
1 (insulin receptor substrate 1), all of them involved in the
transition of an early adenoma to advanced stages [153, 226].
Furthermore, PTEN, a dominant negative regulator of the
Akt, has been shown to be the target of different miRNAs,
such as miR-21, miR-32, miR-92a, and miR-181a (Table 2).
Other signaling pathways involve TGF-𝛽 family that regulates
cellular processes such as proliferation, differentiation, apop-
tosis, and migration. Several miRNAs have been described to
regulate TGFBR2, such as miR-17-5p, miR-20a, miR-21, miR-
23b, miR-106a, and miR-301a. Particularly, miR-21, activated
by the Wnt signaling pathway, is involved in stemness by
regulating TGFBR2 signaling [243]. The oncogenic miR-17-
92 cluster, that is modulated by c-Myc, represses TGF-𝛽
responses by silencing TGFBR2 and SMAD4.
The tumor suppressor p53 is also involved in CRC by
modulation of the response to different stress signals and
controlling processes as senescence, cell cycle arrest, apopto-
sis, invasion, and metastasis [221, 226, 239]. Bioinformatics
sequence analyses propose that up to 46% of the miRNA
potential promoters contain a p53-binding site [215]. Several
miRNAs are related to p53, among them are the following:
let-7i, miR-20a, miR-21, miR-25, miR-34a/b/c, miR-145, miR-
181b, miR- 183, miR-195, miR-215, and miR-451. Interestingly,
themiR-34 family is p53-inducible;miR-34a is upregulated in
CRC patients. A positive feedback loop betweenmiR-34a and
p53 has been proposed as miR-34a activates p53 by targeting
sirtuinmRNA, a key regulator of p53 activity.Moreover, miR-
34a downregulates transcription factor E2F and upregulates
p53 in several cancers such as CRC [221].
EMT, that plays an important role in tumor progression,
invasiveness, and therapeutic failure, is also regulated by
Wnt and Notch signaling pathways through increasing levels
of 𝛽-catenin that translocates to the nucleus and ultimately
induces specific genes essential for EMT triggering by Wnt
or by activation of NF-𝜅B or TGF-𝛽 pathways by Notch.
Several EMT-associated miRNAs are involved in CRC such
as the p53 responsive miR-200 family (miR-200a/b/c, miR-
141, and miR-429), whose downregulation is believed to be
an essential feature of EMT. In addition, miR-146a and miR-
203 are also involved in colon CSC regulation via EMT
signaling pathways. The first one is upregulated by the EMT
inducer Snail that causes the opposite effect on miR-203.
miR-200a and miR-200c are also downregulated in CSCs,
allowing the expression of EMT inducers Zeb1 and Zeb2 with
a concomitant decrease in E-cadherin levels and increased
expression of stem cell markers CD166 and CD133 [162].
Other miRNAs have been described as important for the
maintenance of the cancer stem cell phenotype. miR-215 and
miR-140 are involved in chemoresistance to methotrexate
and 5-FU treatments and in differentiation of CSCs derived
from HCT-116 cells (CD133+, CD44+) possibly by targeting
cell cycle and differentiation related genes [183, 185, 238].
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Similarly, a population of colon CSCs expressing a CD133
surface phenotype from human HT29 colonic adenocarci-
noma cells showed overexpression of 11 and downregulation
of 8 miRNAs which could be potentially involved in the
regulation of stem cell differentiation [244].
As mentioned earlier, the miR-34 family is p53-inducible
and miR-34a is upregulated in CRC patients. However, miR-
34b/c expression is not detectable in several CRC cell lines
probably due to an epigenetic silencing of these miRNAs
[245]. Finally, miRNAs also are regulators of the cancer
epigenome; DNMTs, HDACs, and HMTs are targets of
miRNAs [246]. DNMT3a is downregulated in CRC and is the
target of miR-143. Similarly, miR-342 and miR-185 interact
with the 3󸀠UTR of DNMT1 mRNA [169]. Another example
is miR-140; its overexpression inhibits cell proliferation of
colon cancer HCT 116 (wt-p53) cells but presents lower effect
in HCT 116 (null-p53) cells. This miRNA induces p53 and
p21 expression and produces cell cycle arrest only in cells
containing wild type of p53. Histone deacetylase 4 (HDAC4)
was confirmed to be one of the important targets of miR-
140. In addition, the expression of endogenous miR-140
was significantly elevated in CD133(+hi)CD44(+hi) colon
cancer stem-like cells that exhibit slow proliferating rate and
chemoresistance [183].
5.3. MicroRNA Polymorphisms and CRC Risk. Single nucle-
otide polymorphisms (SNPs) are common variants in the
human genome and have been reported to influence dis-
ease susceptibility. SNPs in miRNAs and related loci are
often located in pri-miRNA and pre-miRNA sequences, seed
sequences, and the 3󸀠UTR regions of target mRNAs [247].
Thus, such polymorphisms might influence miRNA function
in three ways: by altering transcription of the primary
transcript, affecting pri- and pre-miRNA processing, and
modifying miRNA-mRNA interactions [248]. SNPs in miR-
NAsmay ultimately result in the alteration of their expression
and/or maturation, with possible consequences for cancer
development and progression. Furthermore, approximately
half of miRNA genes are located in cancer-related regions
[249].Thus, variations in these sequencesmay result in signif-
icant functional consequences, making them ideal candidates
for cancer risk prediction.
It has been reported that around 35% of analyzed CCRs
are due to genetic or hereditary factors. These factors may
arise from single nucleotide polymorphisms (SNPs) or addi-
tional genetic abnormalities in both coding and noncoding
genes [237]. Taking into account the important role of
miRNAs in the initiation and development of CRC, the
occurrence of SNPs in these molecules has been investigated
as they may influence mRNA function or interrupt miRNA
expression, altering its sequence, the binding site to mRNA,
or even its processing potentially contributing to cancer
susceptibility. Therefore, miRNA polymorphisms may be
used as specific markers of predisposition for CRC diagnosis
and prevention.
SNPs in specific miRNAs may alter the susceptibility of a
patient to develop CRC [248, 250]. SNPs have been detected
in association with an increased risk of CRC affecting either
miRNAs (SNPs in miR-196a, miR-149, and pre-miR-27a or
in miR-257a, affecting binding to 3󸀠UTR of MBL2 mRNA)
[251–253], or the 3󸀠UTR of an mRNA, as in CD86, that
alters binding of several miRNAs (in this case, miR-184, miR-
200a, miR-212a, miR-337, and miR-582) [254], or DOK3,
affecting binding of miR-370 [255]. It has also been observed
that specific SNPs of miRNA-processingmachinery genes (as
DICER or GEMIN3) may affect CRC susceptibility [256]. In
addition, SNPs in miRNAs have been associated with CRC
survival and recurrence, and thus they might be useful in
predicting therapy response. This is the case of two SNPs
(rs4919510 in miR-608 and rs213210 in miR-219-1) that were
genotyped in 1083 CRC patients to evaluate their effect on
clinical outcomes. Carriers of the variant T allele in rs213210
and receiving 5-FU chemotherapy were associated with a
significantly worse survival and an increased risk of relapse,
whereas patients carrying the G allele of rs4919510 and
undergoing adjuvant chemotherapy were at decreased risk of
relapse [257].
5.4. Long Noncoding RNAs in Colorectal Cancer and Reg-
ulation of miRNA Function. The long noncoding RNAs
(lncRNAs) are mainly RNA polymerase II transcripts usually
longer than 200 nucleotides. Some lncRNAs show additional
similarities to mRNA, such as a 5󸀠cap, 3󸀠poly(A) tail, even
though they lack an open reading frame andhave no potential
to encode protein. The number of genes contained within
the gene family of lncRNAs is 214 in humans [http://www
.genenames.org/cgi-bin/genefamilies/set/788]. lncRNA may
be located in the nucleus, chromatin, or cytoplasm; these
different localizations point out to different biological func-
tions. Thus, lncRNAs regulate a variety of key cellular pro-
cesses such as epigenetic silencing, gene transcription and
translation, cell cycle and apoptosis, and cell differentiation
and proliferation [9, 53]. For example, lncRNAs as Xist (X
inactive-specific transcript, related to X-chromosome silenc-
ing) and HOTAIR (HOX Transcript Antisense Intergenic
RNA) interact with chromatin remodeling complexes to
induce changes in chromatin packaging, leading to reduced
target gene expression [258]. In fact, HOTAIR was the first
identified lncRNA that plays a critical oncogenic role through
epigenetic regulatory mechanisms [259]. lncRNAs can also
act as coactivators of transcription factors by interacting
with RNA-binding proteins, and this interaction alters the
localization and activity of the proteins. Additionally, lncRNA
transcripts could competitively inhibit the ability of miRNAs
to interact with their mRNA targets. They act as miRNA
sponges sequestering miRNAs analogous to how artificial
miRNA sponges function (Figure 3) [103, 260]. However,
although empirical evidence supporting the hypothesis that
competitive endogenous RNAs (ceRNAs) as lncRNAs, circR-
NAs, or pseudogenes can act as miRNA sponges, recent stud-
ies that model transcriptome-wide binding-site abundance
suggest that physiological changes in expression of most
individual transcripts will not compromise miRNA activity
[261].
The number of research papers and reviews dealing with
lncRNAs and their involvement in cancer is exponentially
increasing every year. Figure 1(a) (inset) shows the evolution
of the number of papers along the last years. Several reviews
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recapitulate the knowledge in this area [9, 46, 47, 53, 262–
264].Herewe describe only the function of a reduced number
of lncRNAs and mainly those that are involved in CRC.
lncRNAs exhibit unique profiles in various human can-
cers, reflecting disease progression and serving as a predictor
of patient outcome [265]. Their roles as drivers of tumor
suppressors and oncogenic function have been described in
different types of cancer [266]. Several studies have high-
lighted the role of lncRNAs in the development of CRC and
their involvement in chemoresistance of CRC cells [264, 267].
They are involved in processes related to CRC progression
through stimulating or inhibiting cell proliferation, apop-
tosis, differentiation, invasion, and metastasis. CRC-related
lncRNAs have been described to regulate gene expression
by a broad range of mechanisms [267] such as (i) by epige-
neticmodifications (DNAmethylation, histonemodification,
chromosomal instability, X-chromosome inactivation, and
genomic imprinting), (ii) by lncRNA-miRNA interactions,
(iii) by their actions as small RNAs or miRNA precursors
or pseudogenes, (iv) by lncRNA-protein interactions, and
(v) through their function as structural RNAs, in scaffolding
ribonuclear protein complexes. In addition, as some lncRNAs
have been detected in human body fluids by PCR, such as
in plasma and urine, they have also been suggested as novel
potential biomarkers for CRCdiagnosis and prognosis as well
as in the prediction of the response to therapy [268].
Interactions between lncRNAs and RNA sequences have
been described as a regulatory posttranslational mechanism.
In this way, lncRNAs can function as competing endoge-
nous RNAs, miRNA sponges, or as pseudogenes to serve
as decoys for miRNAs. As a result, alterations in target
genes or in the biological function of the miRNAs could be
expected. This mechanism of inhibition of miRNA activity
was discovered in 2007 studying the phosphate homeostasis
in Arabidopsis thaliana (Table 1). The non-protein-coding
RNA IPS1 (Induced by Phosphate Starvation 1) contains
a motif with sequence complementarity to miR-399, the
phosphate starvation-induced miRNA. However, the pair-
ing is interrupted by a mismatched loop at the expected
miRNA cleavage site in IPS1. Thus, IPS1 RNA is not cleaved
but instead sequesters miR-399 [104]. In mammalian cells,
Ebert and coworkers established the name “miRNA sponges”
describing the specific competitive inhibitors from tran-
scripts expressed from strong promoters which contained
multiple tandembinding sites to severalmiRNA seed families
[103]. In this way, as we comment later on, several CRC-
related lncRNAs may also regulate gene expression in CRC
not only by binding to target proteins but also by binding
to miRNAs and, consequently, preventing specific miRNAs
from binding to their target mRNAs.
A clear example of miRNA sponge is the lncRNA HULC
(Highly Upregulated in Liver Cancer) that is located on the
human chromosome 6p24.3. It is formed by two exons and a
500 bp intron and contains a 3󸀠poly(A) tail and a conserved
miR-372 target site [269]. HULC binds to its target miR-372
and acts as a sponge inhibiting the binding of miR-372 to
the mRNA transcript. HULC is overexpressed not only in
hepatocellular carcinoma but also in hepatic CRC metastasis
whereas, in normal tissues, primary CRC, or those cancers
that metastasize to lymph nodes, its expression is null [270,
271]. The involvement of HULC in CRC metastasis to the
liver suggests its role as a new biomarker for the evaluation
of hepatic metastasis potential of CRC.
Loc285194 (or LSAMP antisense RNA 3) is a lncRNA
with more than 2 kb in length, which contains 4 exons and
is present in the focal region of chr3q13.31 (osteo3q13.31),
which is the most altered region in osteosarcomas. It has two
binding sites for miR-211 in its exon 4 and acts as a potential
tumor suppressor as deduced from knockdown experiments,
which showed an increased cell proliferation. It has been
described that loc285194 is downregulated in colon tumor
specimens compared with the normal ones and is a direct
transcriptional target of p53 through the negative regulation
of miR-211 [264, 272]. Interestingly, miR-211 promotes cell
growth and represses loc285194 expression, thus creating a
reciprocal repression feedback loop.
In addition to binding miRNA, several studies have
demonstrated that lncRNAs can regulate gene expression
by acting as miRNA precursors. In this way, lncRNA H19
(located in chromosome 11q15.5 and 6295 nt in length) has
different roles in CRC. It functions as miRNA sponge, as a
miRNA precursor, and was also described as an epigenetic
regulator [264]. Thus, it is a good potential target for CRC
treatment. H19 can promote EMT progression and accelerate
tumor growth by acting as competing endogenous RNA for
miR-138 and miR-200a in CRC [273]. Moreover, H19 can be
processed to yield the precursor of miR-675 [274] and its
expression is positively correlated with the level of miR-675
that is involved in the downregulation of Rb expression [275].
The sequence ofmaturemiR-675 alignswith a sequence of the
3󸀠-UTR of Rb mRNA, and the level of Rb protein appears to
be negatively correlated with the levels of both H19 and miR-
675 in human CRC cells [276].
The lncRNAMALAT1 (Metastasis-Associated Long Ade-
nocarcinoma Transcript 1) is located in chromosome 11q13.1
and has a length of 8708 nt. It promotes cell proliferation,
migration, tumor growth, and metastasis in CRC cells.
MALAT1 interacts with and changes the distribution of
splicing factors, such as SR (serine/arginine-rich) proteins.
Depletion of MALAT1 affects the abundance, location, and
activity of SR proteins and changes the alternative splicing of
a series of pre-mRNAs [277].
lncRNAs can also function as diagnostic and prognostic
biomarkers for CRC. CRNDE (Colorectal Neoplasia Differ-
entially Expressed) and HOTAIR, for example, are upregu-
lated in neoplastic tumor tissue and in the blood of CRC
patients [278, 279].The lncRNACRNDE is highly elevated in
CRC, is transcribed from chromosome 16, and interacts with
components of the polycomb repressive complex 2 (PRC2)
and CoREST complexes [280]. In addition, HOTAIR is a
lncRNA that plays a role as an oncogenic molecule. It is
located on chromosome 12q13.13, has 2.2 kb of length and
6 exons, and has a 3󸀠poly(A) tail. Not only does HOTAIR
interact with PRC2, but also it is necessary for PRC2 occu-
pancy and histone H3 lysine-27 trimethylation of different
genes. PRC2 is a histone methyltransferase that implements
epigenetic silencing during different processes including
cancer development [281]. Interestingly, unlike HOTAIR,
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the lncRNA PCAT-1 (Prostate Cancer-Associated ncRNA
Transcript 1, located in the chromosome 8q24) is repressed by
PRC2. PCAT-1 is upregulated in CRC specimens compared
with normal tissues. There is a positive correlation between
PCAT-1 expression and distantmetastasis of CRC.Theoverall
survival rate of the patients with high expression of PCAT-1
is significantly lower than those with low expression [282].
The CCAT1 (Colon Cancer-Associated Transcript 1;
located in chromosome 8q24.21, 2,628 nt in length) is highly
expressed in CRC compared to normal tissue. CCAT1
upregulation is present in primary CRC tumors, including
precancerous polyps, lymph nodes, blood, and distant CRC
metastasis [283]. Its increased expression was also correlated
with the clinical stage of the patients, lymphnodesmetastasis,
and survival time after surgery. CCAT1 functions as an
oncogene; it is located close to the transcription factor c-
Myc gene and upregulates it, promoting tumor cell prolifer-
ation and migration. Moreover, c-Myc could induce CCAT1
transcription by directly binding to its promoter region.
CCAT1 expression is upregulated in CRC cells and promotes
cell proliferation and invasion. These findings suggest that
c-Myc-activated lncRNA CCAT1 expression contributes to
colon cancer tumorigenesis andmetastatic process and could
predict the clinical outcome of CRC and be a potential target
for lncRNA direct therapy.
Interestingly, lncRNAs seem to be also involved in
chemoresistance of CRC cells. In vitro studies revealed the
downregulation of the lncRNA snaR (small NF90-associated
RNA) and BACE1-AS (BACE1 antisense RNA) in 5-FU
resistant CRC cells, contributing to increase viability and
inhibiting apoptosis without altering the cell cycle [284].
Conversely, the overexpression of the lncRNAUCA1 (urothe-
lial carcinoma associated 1) enhances cell proliferation and 5-
FU resistance in colorectal cancer by inhibiting miR-204-5p
possibly acting as a sponge for this miRNA [285].
Finally, we will consider two lncRNA examples of
molecules related to p53 and CRC. The lncRNA TP53TG1
(TP53 target 1) located in chromosome 7q21.12 is critical for
the correct response of p53 toDNAdamage and its expression
is induced by p53 under conditions of cellular stress. Diaz-
Lagares and coworkers have described that TP53TG1 under-
goes cancer-specific promoter hypermethylation-associated
silencing. TP53TG1 binds to the multifaceted DNA/RNA-
binding protein YBX1 to prevent its nuclear localization and
thus the YBX1-mediated activation of oncogenes. TP53TG1
epigenetic inactivation in HCT-116 CRC cells releases
the transcriptional repression of YBX1-targeted growth-
promoting genes and creates a chemoresistant tumor [286].
The long intergenic noncoding RNA-p21 (lincRNA-p21; ∼
3.1 kb, 2-exon transcript, located near the p21 gene) has a
p53-binding motif in its promoter. It acts to repress many
genes transcriptionally regulated by p53 and is aberrantly
expressed in several types of cancer, including CRC. Experi-
mental evidence using 30 CRC tissues, their adjacent normal
mucosa, and several CRC cell lines showed that lincRNA-p21
decreases which contributes to the elevation of 𝛽-catenin in
CRC. It was also observed that the expression of lincRNA-
p21 increases following radiation exposure and enforced
expression of the lincRNA enhances the CRC sensitivity to
radiotherapy, by promoting cell apoptosis [287]. Consider-
ing the mechanism of gene regulation, the heterogeneous
nuclear ribonucleoprotein K (hnRNP-K) associates with the
promoters of many genes repressed by lincRNA-p21 in a
lincRNA-p21 dependent manner. Dimitrova and coworkers
[288] have described that lincRNA-p21 interacts with the
hnRNP-K through its 5󸀠 end and influences gene expression
as a coactivator of p21 expression promoting the expression
of polycomb target genes. After loss of lincRNA-p21, the
expression of p21 decreased and, although hnRNP-K was
present, the expression of the polycomb target genes was
downregulated and the chromatin state of the genes was
altered.
5.5. Circular RNAs in Colorectal Cancer and Their Role as
miRNA Sponges. Circular RNAs (circRNAs) were reported
more than 30 years ago by electron microscopy [289] and
later on as several abnormally spliced transcripts in which
exons from a candidate tumor suppressor gene (DCC) were
scrambled during the splicing process in vivo [290]. However,
they were considered as rare molecules that resulted from
splicing artefacts or gene rearrangements. CircRNAs were
rediscovered from RNA sequencing (2012/2013) and recent
studies reporting high abundance, great diversity, and tissue
and development specific expression indicate that they are
not just a result of splicing errors. These studies have discov-
ered thousands of endogenous circRNAs inmammalian cells,
among them more than 2,000 circRNA in humans.
circRNAs are RNAmolecules that form covalently closed
continuous loops with joined 3󸀠 and 5󸀠 ends. They mainly
arise from protein coding genes, from exons (exonic cir-
cRNA) or introns (intronic circRNA), bymodels of exon self-
circularization, by lariat-driven circularization, or by back-
splice events [291, 292]. In this last process, the downstream
exons (3󸀠 splice donor site) are spliced to upstream exons
(5󸀠 splice acceptor site) in the primary transcript, yielding
a circular transcript. Reverse complementary sequences or
RNA-binding proteins are necessary for circRNA biogenesis.
For intronic lariat-originated circRNAs, a consensus motif
containing a seven-nucleotide GU-rich element at the 5󸀠
splice site and an eleven-nucleotide C-rich element upstream
the branchpoint has been reported [292].
A characteristic of circRNAs is their stability and resis-
tance to RNase R. They are related to different cancers,
including CRC, where they exhibit an aberrant expression.
Bachmayr-Heyda and coworkers [293] have reported that the
ratio of circular to linear RNA isoforms was always lower in
tumor compared to normal colon samples and even lower
in CRC cell lines. A negative correlation between this ratio
and the proliferation index, which could infer that circRNAs
accumulate in nonproliferating cells, was described.They also
predicted more than 1,800 circRNAs in human normal colon
mucosa and tumor samples of CRC patients, a number which
is in line with other reports about circRNAs.
RNA-seq analyses revealed that circRNAs were enriched
in exosomes compared to the producer cells and more than
1,000 circRNAs were identified in human serum exosomes.
Exosomes contain a specific cargo of protein, mRNA, and
miRNA species, which can modulate recipient cell behaviors
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and may be used as biomarkers for diagnosis of human
diseases. Li and coworkers described for the first time the
presence of abundant circRNAs in exosomes and, interest-
ingly, revealed that serum exosomal circRNAs were able to
distinguish CRC patients from healthy controls. Compared
to healthy subjects, 67 circRNAs were absent and 257 new
circRNA species were detected in CRC patients [294].
circRNAs have been proposed as potential biomarkers for
cancer diagnosis and targeted therapy [295, 296]. Further-
more, circRNAs associate with cancer-relatedmiRNAs acting
as miRNA sponges (Figure 3), binding to RNA-associated
proteins to form RNA-protein complexes, and then regulat-
ing gene transcription [297]. Memczak and coworkers [296]
found that a human circRNA, antisense to the cerebellar
degeneration-related protein 1 transcript (CDR1as, renamed
ciRS-7: circular RNA sponge for miR-7) was densely bound
by miRNA effector complexes and harbors more than 63
conserved binding sites for miR-7 and is densely bound
by AGO protein but not by unrelated proteins. Thus, ciRS-
7 impairs the regulatory effect of miR-7 that, as we have
previously described, is a tumor suppressor which is down-
regulated in a variety of cancers, among them CRC. As
miR-7 modulates the expression of several oncogenes, ciRS-
7/miR-7 interaction may play important roles in cancer-
related pathways. CiRS-7 can be cleaved by miR-671 and its
associated Argonaute protein, whereas it is not cleaved by
miR-7 andArgonaute 2 [298, 299].The second cirRNAhighly
expressed in murine testes, SRY, also functions as a miR-138
sponge; the circular SRY transcript has 16 binding sites for
miR-138 and coprecipitates withAGO2 [300]. Although some
of the molecular and biological roles played by circRNAs
have been characterized, the role of cirRNAs as new star of
noncoding RNAneeds to be clearly established, the biological
function of some of them remains largely unknown, and very
few circRNAs have been described with the potential to act as
RNA sponges.
Recently, a new type of circRNAs has been described
arising from transcribed exons of distinct genes affected
by chromosomal translocations and that encode oncogenic
fusion proteins involved in tumorigenesis. They are called
fusion circRNAs and can coexist with the oncogenic fusion
proteins contributing to cellular transformation, promoting
cell viability and resistance upon therapy, and have tumor-
promoting properties in in vivo models [301]. The presence
and effects of these f-circRNAs has been shown in acute
promyelocytic leukemia (f-circPR and f-circM9 arising from
gene fusions PML/RARA and MLL/AF9, resp.), in Ewing
sarcoma (f-circEF1 from EWSR1/FLI1 fusion), and in lung
cancer (f-circEA1 from EML4/ALK1 fusion).
6. Colorectal Cancer Treatments
and Biomarkers
6.1. ClassicalTherapies and Response Biomarkers in Colorectal
Cancer. CRC cancer can be triggered by alteration of a
plethora of molecular mechanisms, whose accumulation
ultimately leads to malignant transformation. As previously
mentioned, the most frequent alterations reported in the
onset of CRC are as follows: oncogene activation, tumor
suppressor gene inactivation, mutations in the mismatch
repair (MMR) enzymes, microsatellite instability (MIN),
chromosomal instability (CIN), or epigenetic alterations.
Chemotherapy treatments are directed towards the reversion
of some of the effects caused by these alterations, but their
efficacy is highly variable and requires the development of
new adjuvant therapies against different targets. In addition,
the availability of new biomarkers for CRC will greatly
improve the efficacy of chemotherapy.
Initial standard drugs for CRC chemotherapy (see
Table 3) were 5-fluorouracil (5-FU), leucovorin, or their
combination (FL); these treatments offered an overall sur-
vival of about 8 to 12 months [302]. The introduction
of combined therapies with irinotecan and/or oxaliplatin
(FOLFOX, FOLFIRI, CapeOX, and FOLFIRINOX) showed
significant improvement in disease-free survival and overall
survival [303]. A further step was achieved with the use
of monoclonal antibodies targeting EGFR or the vascular
endothelial growth factor receptor (VEGFR) in combination
with the aforementioned chemotherapeutic agents for the
treatment of metastatic CRC [304–307]. In fact, the use of
these antibodies is now recommended as the standard first-
line chemotherapy in this type of tumors.
The monoclonal antibodies cetuximab and panitu-
mumab, directed against EGFR, inhibit cell proliferation and
tumor growth by binding to the extracellular domain of
the receptor blocking the ligand-induced phosphorylation
of the cytoplasmic domain and, consequently, downstream
signaling (Table 3) [308]. In this context, it is important
to point out that gene mutations in proteins downstream
EGFR may be responsible for cetuximab or panitumumab
resistance even in combined treatments with chemothera-
peutic drugs. KRAS and NRAS have been extensively studied
regarding resistance to chemotherapy regimens that include
these monoclonal antibodies. In fact, in patients with RAS
mutations in exons 2 (codons 12 and 13), 3, or 4, leading to
constitutive activation of the protein, no beneficial effects are
obtainedwith themonoclonal antibody treatments compared
to standard chemotherapeutic regimens; only patients with
wild-type KRAS or NRAS present a significant enhancement
in survival [306, 307, 309–312]. Mutations of other molecular
components of the signaling pathway downstream of EGFR
(Ras-Raf-MEK-MAPKs) have also been evaluated as predic-
tive markers for the anti-EGFR therapy. On this idea, BRAF
mutations seem to be an indicator of poor prognosis even in
wild-type KRAS, but results are still unclear [307, 309, 313,
314].
Antiangiogenic combined therapies are also frequently
used for the treatment of metastatic CRC (Table 3). The
humanized monoclonal antibody bevacizumab is directed
against vascular endothelial growth factor A (VEGF-A),
blocking in this way its binding to VEGFR1 and VEGFR2.
This growth factor is proangiogenic and has been associated
with tumor vascularization, progression, and metastasis, as
well as providing protection against the cytotoxic effects
of chemotherapy drugs. Bevacizumab blocks neovascular-
ization of the tumor and improves the effectiveness of
antitumoral drugs [315]. Patient response to bevacizumab
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Table 3: Conventional chemotherapy treatments and targeted therapy for colorectal cancer.
Treatment Mechanism
Drugs used in conventional chemotherapy treatments
5-fluorouracil
(5FU)
Inhibition of nucleotide biosynthesis. Prodrug. Entering the cell through uracil transport system. Intracellular
transformation into FdUMP, FdUTP, and FUTP.
Capecitabine
(Xeloda)
Metabolic precursor of 5FU. Requiring the activity of carboxylesterase, cytidine deaminase, and uridine
phosphorylase.
Methotrexate
(MTX)
Blocking nucleotide biosynthesis as it is a potent competitive inhibitor of dihydrofolate reductase, an enzyme that
participates in the tetrahydrofolate synthesis (required for de novo biosynthesis of purine and pyrimidine bases).
Leucovorin
(Wellcovorin)
Calcium folinate. Enhancing 5FU activity. It is a 5-formyl derivative of tetrahydrofolic acid and is readily converted to
other reduced folic acid derivatives (e.g., tetrahydrofolate). It does not require dihydrofolate reductase activation and
may activate this enzyme and is used in rescue therapies after methotrexate treatment.
Oxaliplatin
(Eloxatin)
Platinum containing compound that form inter- and intrastrand crosslinks in DNA, blocking replication and
transcription.
Approved by the FDA in 2002.
Cisplatin
(Platinol, CDDP)
Platinum containing compound that form inter- and intrastrand crosslinks in DNA, blocking replication and
transcription.
Irinotecan
(CPT-11)
(Camptosar)
Camptothecin derived prodrug. Irinotecan is activated by hydrolysis to SN-38, an inhibitor of topoisomerase I and,
thus, blocks replication and transcription.
Regorafenib
(Stivarga)
Multikinase inhibitor which targets angiogenic, stromal, and oncogenic receptor tyrosine kinase (RTKs).
Approved by the FDA in 2012.
Combined chemotherapy regimens
FOLFOX
Leucovorin (folinic acid) + 5FU + oxaliplatin (stages III & IV).
Approved by the FDA in 2002 for refractory tumors and in 2004 for first-line treatments of metastatic colorectal
cancer.
CapOX (XELOX) Capecitabine + oxaliplatin (stages III & IV).
FOLFIRI (IFL) Leucovorin (folinic acid) + 5FU + irinotecan (stage IV).
FOLFIRINOX Leucovorin (Folinic acid) + 5FU + irinotecan + oxaliplatin (stage IV).
FL 5FU + leucovorin (folinic acid).Approved by the FDA in 1991 for first-line treatment of metastatic colorectal cancer.
Monoclonal antibodies for targeted therapy of metastatic CRC
Cetuximab
(Erbitux)
Cetuximab is a recombinant, human-mouse chimeric IgG1 monoclonal antibody that binds specifically to the
extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells and
competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth
factor 𝛼.
Approved by the FDA in 2004 for use, in combination with irinotecan, for the treatment of EGFR-expressing,
metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. In 2012, approved
for use in combination with FOLFIRI for first-line treatment of patients with wild-type K-ras.
Panitumumab
(Vectibix)
Human mAb against EGFR (similar to cetuximab).
Approved by the FDA in 2006 for the treatment of patients with EGFR-expressing, metastatic colorectal cancer with
disease progression. on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy
regimens.
Bevacizumab
(Avastin)
Bevacizumab is a recombinant humanized monoclonal antibody that binds to human vascular endothelial growth
factor (VEGF), thereby preventing the interaction of VEGF with its receptors on the surface of endothelial cells.
Approved by the FDA in 2013 for use in combination with fluoropyrimidine-irinotecan- or
fluoropyrimidine-oxaliplatin-based chemotherapy for the treatment of patients with metastatic colorectal cancer.
Ziv-aflibercept
(Zaltrap)
Recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGFR1
and 2, that are fused to the Fc portion of the human IgG1 immunoglobulin. It binds and inhibits VEGF-A, VEGF-B,
and placental growth factor. It blocks angiogenesis and decreases vascular permeability.
Approved by the FDA in 2012 for use in combination with FOLFIRI for the treatment of patients with metastatic
colorectal cancer that is resistant to or has progressed following treatment with an oxaliplatin-containing regimen.
Ramucirumab
(Cyramza)
Human mAb against VEGFR2. Inhibits angiogenesis by blocking the interaction between VEGF and VEGFR2.
Approved by the FDA in 2015 for use in combination with FOLFIRI for the treatment of patients with metastatic
colorectal cancer whose disease has progressed on a first-line regimen containing bevacizumab, oxaliplatin, and a
fluoropyrimidine.
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was thought to be directly related to level of circulating
VEGF-A as several studies linked high VEGF levels to a
poor clinical outcome. However, the use of VEGF levels as
predicted biomarker for treatment with bevacizumab is not
currently advised as inconsistent data have been found. This
may arise from the fact that several other molecules are
involved in angiogenesis, and some of them are been analyzed
as potential biomarkers for bevacizumab response [316–318].
Other approaches against the angiogenic pathway include
the combined use of chemotherapic regimens with ziv-
aflibercept or with ramucirumab. Ziv-aflibercept is a human-
ized fusion protein consisting of VEGF-binding portions
from the extracellular domains of human VEGFR1 and
VEGFR2, which are fused to the Fc portion of the human
IgG1 immunoglobulin. It binds and inhibits VEGF-A, VEGF-
B, and placental growth factor (PlGF), blocking in this way
angiogenesis and decreasing vascular permeability.The com-
bined treatment of metastatic CRC with FOLFIRI with ziv-
aflibercept has shown a significant enhancement in overall
survival [319]. Ramucirumab is a human monoclonal anti-
body against the extracellular domain ofVEGFR2, interfering
with VEGF-A binding and further angiogenic signaling. Its
use combined with FOLFOX or FOLFIRI has also shown
promising results for the treatment of patients withmetastatic
CRC [320–322].
The multikinase inhibitor regorafenib was approved in
2012 by the US Food and Drug Administration for the
treatment of patients with metastatic CRC who have been
previously treated with fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, an anti-VEGF therapy, and
an anti-EGFR therapy (the latter only in those cases with
wild-type KRAS). Regorafenib and its active metabolites
inhibit multiple membrane-bound and intracellular kinases
involved in normal cellular functions and in pathologic
processes (as angiogenesis or tumor growth), including those
in the RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-
𝛼, PDGFR-𝛽, FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A,
RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, andAbl pathways
[323, 324].
Other biomarkers have been analyzed in order to check
the response to monoclonal antibody treatments, mainly
centered in anti-EGFR therapy. Besides KRAS and NRAS,
mutations in PIK3CA, TP53, PTEN, and EGFR have been
proposed as predictive biomarkers with variable success.
Regarding mutations in PIK3CA (which encodes the PI3K
catalytic subunit), conflicting results have been obtained
[325]. It has been proposed that anti-EGFR monoclonal
antibody treatments might be efficient in tumors where p53
is inactivated [326], whereas PTEN loss correlates with lack
of response to cetuximab and panitumumab [325, 327].
6.2. miRNAs as Predictive Biomarkers andTherapeutic Targets
in CRC. As described above, one of the major problems for
themanagement ofCRC is the inherent or acquired resistance
to therapeutic treatments. As miRNAs are important regu-
lators of cell signaling pathways involved in carcinogenesis,
progression, invasion, angiogenesis, and metastases in CRC,
they are being analyzed as potential predictive and prognostic
factors, or even as therapeutic targets themselves. In fact,
the involvement of the dysregulation of several miRNAs has
been linked to tumor progression and response to anticancer
therapies [144, 328–330]. miRNAs are also required for nor-
mal immune system development and function and aberrant
expression of miRNAs has been observed in various tumor
types leading to immune disorders or immune evasion.Thus,
miRNAs could also be considered as potential targets in
the regulation of the immune response in CRC in order to
develop new therapeutic strategies [331].
miRNAs are very stable molecules that resist prolonged
storage, exposure to high or low pH values, or even boil-
ing and can be detected in archival tissue specimens and
serum. These characteristics are quite interesting for their
use as biomarkers as they can be extracted for analysis
from blood, plasma, serum, and various body fluids and
in frozen or formalin-fixed paraffin-embedded tissues [332,
333]. The discovery that extracellular miRNAs circulate in
the bloodstream and that such circulating miRNAs are quite
stable raised the possibility that miRNAs may be probed
in the circulation and can also serve as novel diagnostic
makers. These molecules are protected from degradation by
their inclusion in lipid vesicles or by their interaction with
plasma proteins, as was originally shown by El-Hefnawy
and coworkers [334]. Depending on their size and mode of
release from cells, miRNAs can be included into exosomes,
microvesicles, or apoptotic bodies. Exosomes (50–100 nm
in diameter) originate from the endosome and are released
from cells when multivesicular bodies fuse with the plasma
membrane; microvesicles are released from the cell through
blebbing of the plasma membrane. miRNAs are also found
in circulation in microparticle-free form, associated with
high-density lipoproteins (HDL) or bound to RNA-binding
proteins such as Ago2 or NPM1 (nucleophosmin). It is not
known how these miRNA-protein complexes are released
from the cell; theymay be released passively, as byproducts of
dead cells, or actively, in a miRNA-specific manner, through
interaction with specific membrane channels or proteins
[335].
Cells can select some miRNAs for cellular release while
others are mainly retained within the cell. Pigati and cowork-
ers analyzed normal and malignant epithelial cells and
reported that 66% of the miRNAs were released in quantities
that reflected their intracellular level and 13% were selectively
retained in the cell with very low secretion, but 21% of the
miRNAs were actively secreted [336]. They also observed
that pre-miRNAs were also secreted together with mature
miRNAs. In fact, some cells secrete preferentially the precur-
sor forms rather than the mature ones, as reported for mes-
enchymal stem cells [337]. The release of miRNA-containing
exosomes seems to be ceramide dependent; human CRC
cells release miRNAs in ceramide-rich exosomes, and inhi-
bition of enzymes involved in ceramide biosynthesis (as
sphingomyelin phosphodiesterase 3) strongly decreases the
secretion of miRNAs into exosomes [338].
6.2.1. miRNAs as Diagnostic and Prognostic Markers. miR-
NAs are beginning to be used as diagnostic markers of CRC
[21]. Serum miR-21 and miR-92a have been analyzed as
biomarkers in the diagnosis and prognosis of CRC [339].
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Patients with advanced adenoma or with CRC showed signif-
icantly higher levels compared to healthy controls. They have
been also studied in stool, but they showed lower sensitivity
and specificity than in serum for the detection of CRC [340].
Elevated serum levels of miR-92a correlate well with CRC
and poor survival [339], whereas miR-21 is not specific to
CRC but is also found increased in the plasma of patients
with other cancer types [341]. In another study, high levels
of circulating miR-34a and low miR-150 levels distinguished
groups of patients with polyps from those with advanced
CRC, and low circulating miR-150 levels separated patients
with adenomas from those with advanced cancer [342]. mir-
1290 has been also described as a novel biomarker for early
detection, recurrence, and prognosis in human CRC [343]
In order to achieve a more precise screening for CRC,
panels of plasmamiRNAs have been devised: a panel consist-
ing of eight miRNAs (miR-532-3p, miR-331, miR-195, miR-17,
miR-142-3p, miR-15b, miR-532, and miR-652) could identify
polyps from controls, and a panel of three miRNAs (miR-431,
miR-15b, and miR-139-3p) distinguished stage IV CRC from
controls [344]. miR-135b has been also found to be increased
in CRC and adenomas compared to normal adjacent tissue,
as well as in stool specimens where levels of this miRNA
increased in patients with adenomas compared to those with
CRC and were higher than in control patients or patients
with inflammatory bowel disease. Moreover, miR-135b levels
in stool decreased significantly after surgery, suggesting that
thismiRNAmay act as a biomarker for early-stageCRC [345].
Fecal miR-106a has been also proposed as a useful marker
for colorectal cancer patients with false-negative results in
immunochemical fecal occult blood test [346].
Finally, Ahmed [347] performed a global analysis of
miRNA expression in stool from 12 patients with CRC (3
per stage; 0-I, II, III, and IV) and 3 controls and found
141 miRNAs overexpressed in CRC and 61 with reduced
expression. After selecting 20 miRNAs, they carried out an
additional study using modified real-time quantitative PCR
with stool samples from 60 patients (20 per group) and found
12 miRNAs overexpressed in CRC and whose expression
increased with the stage (miR-7, miR-17, miR-20a, miR-21,
miR-92a, miR-96, miR-106a, miR-134, miR-183, miR-196a,
miR-199a-3p, and miR-214). Conversely, they also found 8
miRNAs that showed reduced expression in CRC and that
decreased with stage progression (miR-9, miR-29b, miR-127-
5p, miR-138, miR-143, miR-146a, miR-222, and miR-938).
Taking into account these finding, the authors propose that
a chip can be developed to facilitate diagnosis of CRC from
stool or blood samples.
In addition to diagnosis, miRNAs are beginning to be
considered as promising predictive markers for response to
therapy. On this idea, miR-31-3p and -5p were identified as
good markers of response to cetuximab treatment in wild-
type RAS patients with metastatic CRC as nonresponders
presented significantly higher expression levels of these two
miRNAs compared to responders. However, no association
between time to progression and the expression of these
miRNAs was found in patients treated with panitumumab
[216]. Similar associations have been found for othermiRNAs
and treatments. For example, miR-143 low-level expression
in primary tumors was found as a good predictive factor
for the effectiveness of capecitabine treatment as first-line
monotherapy in patients with metastatic CRC [348]. miR-
320e has been also identified in two clinical trials cohorts as
a novel prognostic biomarker that is associated with adverse
clinical outcome in stage III CRC patients treated with 5-
FU-based adjuvant chemotherapy (FOLFOX) [349]. These
findings have important implications for the personalized
management of CRC patients.
The presence of SNPs in specific miRNA has also been
associated with prognosis and response to chemotherapy
treatments in CRC. The expression of specific miR-492
variants in CRC patients has been reported in association
with a better prognosis and progression-free survival [350].
Regarding response to therapy, several articles describe that
KRAS-LCS6 variant is of particular interest due to an alter-
ation in the binding site of let-7 miRNA at the 3󸀠UTR of K-
Ras. Graziano and coworkers have reported that patients with
metastatic CRC without mutations in BRAF that received
anti-EGFR therapy (cetuximab plus irinotecan) showed a
much lower survival if they presented the KRAS-LCS6 SNP
than patients without it [351]. However, apparently opposite
results were obtained by Zhang and coworkers in patients
with wild-type KRAS treated only with cetuximab and no
irinotecan [219]. Thus, care must be taken when considering
this SNP as a predictive response parameter as it strongly
depends on the chemotherapy regimen and in themutational
status of KRAS and BRAF.
6.2.2. miRNAs Involved in Chemoresistance and Radiore-
sistance. Chemotherapy sensitivity or resistance is strongly
dependent on protein targets that are epigenetically modified
that involve variations in the intracellular expression of miR-
NAs and lncRNAs. The literature regarding the involvement
of miRNAs in the acquisition of resistance in CRC cells to
conventional chemotherapy agents such as 5-FU, oxaliplatin,
or irinotecan is ample (Table 4). Most of the findings rely on
in vitro experiments with cultured cells and some of them
are even controversial. For example, cells resistant to 5-FU
treatment have been reported to have increased expression of
miR-192 and miR-215, whose target is thymidylate synthase
(TYMS), a potential target of 5-FU. Surprisingly, however,
these miRNAs seemed to increase resistance to 5-FU, rather
than improving the drug’s efficacy [186]. On the other hand,
miR-129 or miR-203, whose mRNA target is also TYMS,
behaves in a completely opposite manner; they are downreg-
ulated in 5-FU resistant cells, but their restoration induces
chemosensitivity to this agent [196, 208]. It is also somehow
controversial the fact that let-7g overexpression, that belongs
to a miRNA family normally described as tumor suppressors,
was associated with chemoresistance to S-1 (composed of
5-FU prodrug tegafur, a dihydropyrimidine dehydrogenase
inhibitor, gimestat, and an inhibitor of orotate phosphoribo-
syltransferase, otastat potassium, in a molar ratio of 1 : 0.4 : 1)
in colon cancer [177].
In general, those miRNAs whose expression is upregu-
lated in chemoresistant cells repress the expression of targets
related directly or indirectly to the induction of apoptosis
or to the control of proliferation. An example of the former
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Table 4: miRNAs involved in chemoresistance in colorectal cancer treatments.
miRNA Treatment Verified targets in CRC References
miRNAs overexpressed in chemoresistance to conventional drugs
Let-7g S-1 RAS, cyclin D, c-Myc, E2F, cytochrome c [177]
miR-10b 5-FU BIM [178]
miR-19b 5-FU SFPQ, MYBL2 [179]
miR-20a 5-FU, oxaliplatin BNIP2 [180]
miR-23a 5-FU APAF-1 [181]
miR-31 5-FU ? [182]
miR-140 5-FU HDAC [183]
miR-148a 5-FU, oxaliplatin ? [184]
miR-181b S-15-FU RAS, cyclin D, c-Myc, E2F, cytochrome c [177]
miR192/215 5-FU TYMS, DHFR [185, 186]
miR-203 Oxaliplatin ATM [187]
miR-224 5-FU ? [188]
miR-520g 5-FU, oxaliplatin CDKNIA (p21) [189]
miR-625-3p Oxaliplatin ? [190]
miRNAs downregulated in chemoresistance to conventional drugs
miR-22 5-FU BTG1 [191]
miR-34a 5-FU SIRT1, E2F3, KIT, LDHA [192–194]
miR-122 5-FU PKM2 [195]
miR-129 5-FU BCL2, TYMS, E2F3 [196]
miR-133a Oxaliplatin RFFL [197]
miR-139-5p 5-FU NOTCH1 [198]
miR-141/200c Oxaliplatin ZEB1 [199]
miR-143 5-FU, oxaliplatin BCL2, NFKB, ERK5, IGF1R [200, 201]
miR145 5-FU FLI-1, RAD18 [202, 203]
miR-149 5-FU FOXM1 [204]
miR-153 Oxaliplatin FOXO3 [205]
miR-196a Oxaliplatin HOXA7, HOXB8, HOXC8, HOXD8 [206]
miR-200 cluster 5-FU EMT-related genes [207]
miR203 5-FU TYMS [208]
miR-204 5-FU HMGA2 [209]
miR-222 Oxaliplatin ADAM17 [188]
miR-297 Oxaliplatin ABCC2 [210]
miR-451 Irinotecan ABCC1 [211]
miR-497 5-FU, irinotecan IGF1R [212]
miR-519c 5-FU, oxaliplatin ABCG2, ELAVL1 (HuR) [213]
miR-1915 Oxaliplatin BCL2 [214]
miRNAs overexpressed in chemoresistance to monoclonal antibody-based therapies
miR-17-3p Cetuximab ? [215]
miR-31 Cetuximab ? [216]
miR-126 Bevacizumab, XELOX ? [217]
miR-146-3p Cetuximab IL1A [215]
miR-199a-5p/375 Cetuximab PHLPP1 [218]
miR-486-5p Cetuximab ARHGAP5, ST5, DOCK3, TOB1, PIK3R1 [215]
miRNAs downregulated in chemoresistance to monoclonal antibody-based therapies
Let-7 family Cetuximab, panitumumab KRAS [215, 219]
miR-7 Cetuximab EGFR, RAF1, ERK1/2, AKT [136]
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is miR-153, which is upregulated in resistance to oxaliplatin
in vitro and in vivo. This miRNA represses the expression
of the Forkhead transcription factor FOXO3a repressing in
this way apoptosis through reduced caspase-3 activation,
upregulation of antiapoptotic genes, and downregulation
of proapoptotic ones as PUMA and Bim [205]. Regarding
dysregulation of the cell cycle, it has been proposed that miR-
520g may confer chemoresistance to 5-FU and oxaliplatin
in CRC cells through downregulation of p21 expression. In
addition, p53 inhibits miR-520g expression and the loss of
p53 function causes an increase in the expression levels of
miR-520g, suggesting an important role of this miRNA as a
potential target for therapy to overcome drug resistance in
CRC patients [189].
miRNAs have also an impact on the resistance of CRC
to targeted chemotherapy or combined regimens (Table 4).
The overexpression of several miRNAs has been directly
related to resistance tomonoclonal antibody-based therapies.
As previously discussed, miR-31 is upregulated in metastatic
CRC and can be used as a predictive marker of the efficacy to
cetuximab treatment but not to panitumumab. However, it is
yet unclear the mechanism by which this miRNA enhances
resistance [216]. Upregulation of miR-199a-5p and miR-375
induces cetuximab resistance in CRC cells by targeting the
tumor suppressor PHLPP1, a negative regulator of the Akt
pathway [218]. Ragusa and coworkers correlated high expres-
sion levels of miR-146b-3p and miR-486-5p with resistance
to cetuximab in patients with constitutive activation of KRAS
signaling, suggesting their involvement in EGFR pathway
[215]. In the same study, they describe that upregulation
of members of the let-7 family may enhance sensitivity of
metastatic CRC to anti-EGFR treatments by targeting K-Ras
mRNA. In a similar way, Suto and coworkers showed that
miR-7 induced sensitivity to cetuximab in CRC cell lines by
targeting EGFR and RAF1 mRNAs and suppressing ERK1/2
and phospho-Akt expression [136]. miR-126 was described
as a potential tumor suppressor involved in regulation of
angiogenesis and thus was suspected to be involved in the
outcome of bevacizumab treatment. However, although high
expression levels of miR126 in primary CRC tumors were
detected in XELOX responsive patients [352], high levels of
circulating miRNA-126 were associated with bevacizumab
plus XELOX resistance [217].
miRNA deregulation in CRC tissues may also influence
the activity of signaling pathways involved in the response
to combined chemo- and radiotherapy of these tumors. Col-
orectal cell lines exposed to continuous low-dose radiation
overexpress miR-622, and this overexpression is maintained
in surviving cells. Resistance arises from a downregulation
of Rb, whose mRNA is a direct target of miR-622. In fact,
overexpression of Rb in these cells reverses radioresistance
[353]. The opposite effect has been detected for miR-630
and miR-106b, whose upregulation is directly correlated to
radiosensitivity by targeting BCL2L2 and TP53RK mRNAs
(miR-630), both involved in cell survival and apoptosis
inhibition [354], or PTEN and p21 (miR-106b), leading to
the activation of Akt which promotes cell survival and
proliferation [355]. Long noncoding RNAs are also involved
in radiosensitivity.The long intergenic lincRNA-p21 has been
shown to increase the sensitivity of radiotherapy for human
CRCby targeting theWnt/𝛽-catenin signaling pathway [287].
6.2.3. miRNA as Therapeutic Targets and Tools in CRC. As
previously discussed, the expression of miRNAs is altered in
CRC; some miRNAs may act as oncogenes (oncomiRs) and
others as tumor suppressor genes. It is feasible to manipulate
their expression by injecting miRNAs in a similar way to
the use of antisense mRNAs or RNAi, blocking the activity
of oncomiRs or well replacing tumor suppressor miRNAs to
restore loss of function. In any case, before applying these
technologies, it is essential to establish first which miRNAs
are up- and downregulated in CRC, followed by loss/gain
studies in vitro or in animal models. After identifying
potential miRNA targets, a pharmacological analysis must be
carried out with in vivo miRNA delivery studies and analysis
of pharmacokinetic and pharmacodynamics. Finally, clinical
trials should be carried out to evaluate efficacy and safety of
the potential treatments [356].
Mature miRNAs can be inhibited using different tools:
antisense oligonucleotides (anti-miRs, antagomirs, or ASOs),
miRNA sponges, miRNA masking, anti-miR peptides, or
small molecule inhibitors. A miRNA sponge is a transcript
(mRNA) expressed from plasmids possessing multiple tan-
dem binding sites for targeted miRNAs that block selectively
a whole family of related miRNAs. For example, in breast
cancer cells, Jung and coworkers demonstrated that a multi-
potentmiRNA sponge againstmiR-21, miR-155, miR-221, and
miR-222 strongly inhibited cell migration in a much stronger
way than single miRNA targeting [357]. Sponges have been
widely used to investigate miRNA function in vitro, but their
utility in vivo has been limited to transgenic animals in which
the sponge mRNA is overexpressed in target tissues [358].
Interestingly, it seems that some large and circular noncoding
RNAs as well as pseudogene transcripts could serve as natural
sponges to regulate cellular miRNA availability and lead to
upregulation of downstream target genes [261, 359].
The miRNA masking technology was developed by Choi
and coworkers [360] and consists of single-stranded 2󸀠-O-
methyl-oligonucleotides complementary to miRNA binding
sites in the 3󸀠UTR of target mRNAs that disrupt the inter-
action of specific miRNA-mRNA pairs. An advantage of this
method is that avoids potential off-target secondary effects.
Approaches using small molecule inhibitors to manipu-
late miRNA expression and function are also being devel-
oped. Screening of this type of compounds has identified
small molecules that can specifically inhibit the expression
of miRNAs, as azobenzene, which affects miR-21 expression
[361], or several molecules that inhibit miR-122 that could be
useful for HCV therapy [362].Thesemolecules do not inhibit
target recognition by the miRNAs but rather modulate the
transcription of targeted miRNAs. However, these molecules
are still of limited therapeutic potential due to their high EC
50
values and the lack of specific inhibitors for many miRNAs.
On the other hand, some fluoroquinolone antibiotics, as
enoxacin, have been described to enhance the effect of
siRNAsormiRNAsby increasing the binding affinity of TRBP
to the miRNA precursors. It does not present specificity for
miRNA sequences but induces a global increased expression
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Figure 5: Chemical modifications of miRNA-targeting modulators. Anti-miR oligonucleotides have been chemically modified in order to
achieve better stability against serum nucleases and to increase the binding affinity to targeted miRNAs. Most of the modifications are at the
2󸀠 position of the sugar moiety, as 2󸀠-O-methyl (2󸀠-OMe), 2󸀠-O-methoxyethyl (2󸀠-MOE), and 2󸀠-fluoro (2󸀠-F). Locked nucleic acid (LNA) is a
bicyclic RNA analogue inwhich ribose is locked by introduction of amethylene bridge between the 2󸀠 oxygen and the 4󸀠 carbon of the pentose.
In addition, most anti-miR oligonucleotides contain phosphorothioate backbone linkages in which sulfur replaces one of the nonbridging
oxygen atoms in the phosphate group. Morpholino oligomers replace the ribose with a methylenemorpholine ring (to which bases are
attached) with phosphorodiamidate linkages. PNA oligomers are oligonucleotide analogues in which the ribose-phosphate backbone has
been replaced with a peptide-like structure containingN-(2-aminoethyl)-glycine units. Bothmorpholino and PNA oligomers are uncharged,
which facilitates the interaction with targeted miRNAs.
of miRNAs that could be interesting for tumors where this
expression is lowered [363].
Antisense inhibition of mature miRNAs is nowadays
still the technology which has received more attention,
mainly regarding anti-miRs or ASOs which specifically target
oncomiRs. These anti-miRs bind to the miRISC complexes
blocking the interaction of miRNAs with their endogenous
mRNA targets. This approach has been tested in human
colon carcinoma cells in culture and in mice models of CRC
targeting overexpressed miRNAs. Specific silencing of miR-
135b has been shown to effectively inhibit tumor proliferation
in mice models and to induce apoptosis in SW480 human
colon carcinoma cells [364] or reduce themigratory ability in
HCT-116 cells [345]. In addition to miR-135b, other potential
oncogenic miRNAs have been tested using this knockdown
technology as miR-20a, miR-21, miR-31, miR-95, or miR-
675 in other human colorectal carcinoma cell lines [124, 180,
182, 276, 365]. A potential drawback of this technology is
that unmodified RNA oligonucleotides are quite sensitive to
serum nucleases for their potential in vivo administration.
In addition, they cannot penetrate cell membranes with-
out being modified or encapsulated to enable their entry
into the cell cytoplasm. For these reasons, several lines of
research are directed towards increasing resistance of anti-
miRs to nucleases by chemical modification, to enhance
their binding affinity to mRNA targets and to improve their
pharmacokinetics and pharmacodynamics in vivo (Figure 5).
The 2󸀠-O-methyl (2󸀠-OMe) modification was one of the first
attempts (reported in 2004) to successfully block miRISCs
in Drosophila melanogaster and in human cultured cells.
However, although these 2󸀠-OMe modified oligonucleotides
were more effective, they were still susceptible to degradation
by serum nucleases. To increase resistance, oxygens in the
phosphate backbone were replaced with sulfur atoms to
form phosphorothioate-modified miRNAs. These modifica-
tions showed also improved pharmacokinetics [366]. Further
improvement of anti-miR showed that modifications were
more efficient in the 3󸀠 end and that linkage of cholesterol
to this end also increased the pharmacology and efficacy
of specific anti-miRs [367]. Other modifications at the 2󸀠
sugar position have been proposed to increase the efficacy
of anti-miRs, such as 2󸀠-O-methyoxyethyl (2󸀠-MOE), 2󸀠-
fluoro (2󸀠-F), and locked nucleic acid (LNA; bicyclic nucleic
acid with a methylene bridge between 2󸀠 oxygen and the 4󸀠
carbon) modifications (for review see [329, 368]). Among
these modifications, LNA has shown an exceptional binding
affinity to miRNAs, which has made it possible to achieve
efficient inhibitions with rather short sequences that bind
only the seed regions of the target miRNAs [369].
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Anti-miR peptides are artificial peptides (peptide nucleic
acids or PNAs) that behave as uncharged DNA or RNA
analogues in which the sugar backbone has been replaced
with a peptide-like backbone which consists of N-(2-
aminoethyl)glycine units to which the nucleobases are
attached. These PNAs bind to target miRNA more tightly
than equivalent oligonucleotides, are more stable, and can
be administered systemically with low toxicity. Similarly,
morpholinos are uncharged oligonucleotide analogues with a
slightly increased binding affinity to complementarymiRNAs
[329, 368].
Other approach for miRNA therapeutics deals with the
recovery of the activity of tumor suppressor miRNAs that are
downregulated or not expressed at all in CRC or other types
of cancer. For this purpose, current research is using synthetic
RNAduplexes that, as described above formiRNA inhibition,
harbor chemical modifications to improve stability, nuclease
resistance, and cellular uptake [368, 370]. These are referred
to as miRNA mimics and contain one strand identical to
the miRNA of interest (guide or antisense), whereas the
opposite strand (passenger or sense) is normally less stable.
This passenger strand has been linked in some studies to
a molecule as cholesterol or peptides to enhance cellular
uptake. In addition, chemical modifications are normally
introduced to avoid loading of this strand into the RISC
complex, as 5󸀠-O-methylation, but still allowing its degra-
dation after separation of the antisense strand [371]. The
antisense strand has to be loaded into the RISC complex
and thus, its modifications for stability have to be carried
out with more care to avoid interference with the formation
of the complex. This therapeutic approach has been tried in
colon and hepatocellular carcinomas and hepatic metastasis
(that may arise from primary CRC) and, in cell culture
and in mice orthotopic models, recovers the expression of
downregulated tumor suppressor miRNAs miR-26a, miR-
33a, miR-34a, or miR-145. Overexpression of these miRNAs
with mimics resulted in inhibition of cancer cell proliferation
and apoptosis, or in tumor reduction, prolonged survival, and
disease protection in animals [356, 372–374]. In 2013, the first
miRNA mimic entered phase 1 trial in patients with primary
liver cancer or metastatic cancer with liver involvement
under the name ofMRX34, a double-stranded RNAdelivered
by Smarticles (licensed liposomes which comprise different
mixtures of palmitoyl oleoyl phosphatidyl choline, dioleoy-
loxytrimethylammoniumpropane, 1,2-dimyristoylglycerol-3-
hemisuccinate, and cholesterol) (http://www.mirnatherapeu-
tics.com/) [113]. However, multiple immune-related severe
adverse events were observed in patients dosed with MRX34
over the course of the trial and the company decided to halt
the study.
Restoration of tumor suppressor miRNAs still presents
several challenges. Treatment with the synthetic RNA
duplexes may recover the expression of downregulated miR-
NAs, but there is always a risk of overexpressing them or
that cells that normally do not express the targeted miRNAs
suffer off-target effects. These potential unwanted side effects
of miRNA mimics reveal the importance of improving the
targeted delivery to the appropriate cells or tissues, also quite
important when silencing oncomiRs.
As discussed above, the use of miRNA therapeutics in
vivo presents considerably more challenges than research in
vitro. Much progress has been made regarding the resistance
of therapeuticmiRNAs to nucleases or to increase the binding
affinity of anti-miRs or miRNA mimics to mRNA targets
in the miRISC complexes. However, the main challenge for
development of miRNA-based therapeutics is the design of
efficient and safe methods for the delivery in vivo of miRNAs
to targeted tissues or cells [329, 368]. Research has been
mainly centered in delivery of siRNAs, but these advances can
be readily applied to miRNA mimics and anti-miRs.
Conjugation of cholesterol to the 3󸀠 end of miRNAs
was one of the first attempts; it allowed incorporation of
siRNAs or miRNA mimics into HDL and LDL lipopro-
teins [375]. Since them, several other molecules have been
checked, as 𝛼-tocopherol linked to the 5󸀠 end of the antisense
strand, receptor-targeting ligands for cell binding (i.e., CpG-
containing oligonucleotides directed for cells expressing
TLR9 receptor), or cell-penetrating peptides for crossing cell-
surface or endosomal membranes, as pHLIP.This peptide is a
38-amino-acid-long hydrophobic, negatively charged peptide
that, under slightly acidic conditions (around pH 6.5), inserts
as a helix into cell membranes.This peptide was unsuccessful
when used with oligonucleotides but worked efficiently with
PNAs linked via a disulfide bond [376].
Lentivirus- or adeno-associated virus-based miRNA
expression constructs have been also studied for the delivery
of tumor suppressor miRNAs, and some of these constructs
are being used in several clinical trials for gene therapy.
Liposome-based methods have been also widely tested for
the encapsulation of siRNAs and miRNAs or analogues.
These liposomes can even be coated with carbohydrates,
peptides, or antibodies to direct them towards cell types that
express specific receptors or antigens. Similarly, siRNAs or
miRNAs can be incorporated in polymer-based nanoparticles
(10–100 nm), as those containing polyethyleneimine that have
been reported to be efficient for the therapy of CRC in cell
culture and mouse xenografts by restoring miR-33a or miR-
145 function [373, 374]. Antibody-based methods have been
also described. The most common approach is to design
chimeric proteins consisting of an RNA-binding protein (as
protamine or synthetic positively charged peptides) fused
to Fab or single-chain variable fragments from antibodies
directed towards antigens expressed in targeted cells.
Several challenges remain to be addressed before miRNA
therapeutics can reach safely the clinic. A first one is asso-
ciated with the fact that, from the 2588 mature miRNAs
described so far in humans (miRBase 21), only around 200 are
sufficiently expressed to be feasible targets for therapy [329].
Many of these miRNAs belong to families with similar seed
regions and thus, it is quite normal that, for example, an anti-
miR directed against one member of one of these families
may affect also other miRNAs with similar or identical seed
region under physiological conditions. A second important
aspect to be considered is that miRNA mimics or anti-
miRs can elicit an immunological response mainly through
the innate immune system, whose cells express Toll-like
receptors (TLRs) [377]. These receptors recognize dsRNAs
(TLR3) or single-stranded GU-rich RNAs (TLR7 and TLR8)
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and evoke an interferon-𝛼 response by plasmacytoid den-
dritic cells [378]. This response can be reduced by chemical
modification of the sense strand; on this idea, Hornung
and coworkers observed that LNA modifications strongly
reduced the immunostimulatory effects of siRNAs [378].
Although these modifications may be efficient in order to
get nuclease resistance or stability of miRNAs, some of
them may elicit other undesirable responses, affecting, for
example, blood coagulation, activation of the complement
cascade, the immune system (phosphorothioate-containing
oligonucleotides), or liver toxicity (i.e., LNA-modified anti-
miRs) [329]. Finally, much care has to be taken when
administering anti-miRs in vivo as blocking the function
of certain oncomiRs may negatively affect physiological
responses where those miRs exert specific functions. Thus,
cell or tissue targeting is essential to avoid these potential
problems. In addition, it is also difficult to ensure whether
the appropriate dose of miRNA reaches targeted cells and
becomes incorporated into RISCs. Some of these potential
problems could be addressed with more efficient delivery
systems in order to direct miRNAs towards specific cells or
tissues, facilitate intracellular transport, and further release
into the cytoplasm. This could allow decreasing the thera-
peutic dose of miRNAmimic or anti-miR in vivominimizing
adverse effects.
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